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ABSTRACT 
 
SIMA ZACHAREK: Evaluating downstream targets of cullin4-dependent E3 ligases and of 
D-type cyclins: implications for the dysregulation of ubiquitination and cell growth in cancer 
(Under the direction of Yue Xiong) 
 
Cyclin D1 and cullin4 (CUL4) are two proteins known to be upregulated in cancer.  Cyclin D1 
functions to regulate the cell division cycle and cell growth, while CUL4 assembles E3 ubiquitin 
ligase complexes that function to ubiquitinate target proteins, often marking them for degradation.  
However, the downstream effectors of their oncogenic activities are not fully characterized.  
Therefore, the aim of this study was to discover novel targets of the D-type cyclins and of CUL4, and 
to better describe the E3 ubiquitin ligase complexes assembled by CUL4.  We identified the TSC1-
TSC2 tumor suppressor complex, a key negative regulator of cell growth, as a cyclin D-interacting 
complex, and demonstrated that D-type cyclins could down-regulate the activity of TSC1-TSC2 by 
both CDK (Cyclin Dependent Kinase) -dependent and –independent mechanisms.  In a separate line 
of studies, I conducted a genetic analysis of mutants of Cul4 and one of its putative substrate receptor 
molecules, Ddb1 (Damaged DNA Binding protein 1) in Drosophila, and established that CUL4DDB1 
plays an essential role in cell growth, proliferation, and development.  These studies suggested a 
number of novel substrates of the CUL4DDB1 ligase, and also served to clarify the role of CUL4DDB1 in 
controlling the degradation of the replication licensing factor CDT1/DUP during the cell cycle.  
Collectively, these analyses of the D-type cyclins and CUL4 broaden our understanding of the 
consequence of their disruption in cancer development. 
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CHAPTER I 
 
Introduction 
 
Of the numerous of cell divisions that occur over a lifetime, most transpire under 
normal constraints and remarkably without incident. The occurrence of cancer, which results 
from abnormal and uncontrolled cell division, in fact arises less than once per human lifetime.  
Multiple checks and balances are in place to prevent the development of cancer, but if 
adequate restraints on proliferation are breached, a somatic cell can acquire the ability to 
propagate limitlessly under conditions in which their normal cellular counterparts arrest, become 
senescent, or undergo programmed cell death.  The development of cancer is an evolutionary 
process in which the acquisition of genetic and epigenetic alterations confers a selective 
advantage to the cell at specific stages of tumorigenesis, leading to unimpeded clonal 
expansion of the neoplastic cell (Foulds, 1954; Lowe et al., 2004). 
 
Genetic alterations in cancer 
Cancer is a genetic disease, arising from direct and indirect alterations in gene 
expression.  Factors such as environmental influences, infectious agents, and aging also 
contribute to cancer development.  Some cancers are initiated by cancer predisposition 
syndromes such as retinoblastoma, Cowdens disease, Li-Fraumeni syndrome, or von Hippel-
Lindau syndrome, and stem from inherited germline mutations affecting the pRb, PTEN, 
p53/ Chk2, or VHL genes, respectively (Turnbull and Hodgson, 2005).  Mutations in these 
 2
and many other genes can also arise sporadically in somatic cells, initiating the neoplastic 
process.  With the subsequent stepwise accumulation of further somatic mutations and 
alterations, gross chromosomal abnormalities and extensive changes in gene expression 
patterns often develop in the neoplastic cell.    
 
Genes frequently altered in cancer can be classified as oncogenes, tumor suppressor 
or ‘gatekeeper’ genes, and stability or ‘caretaker’ genes (Vogelstein and Kinzler, 2004).  
While oncogenes and tumor suppressor genes are generalized as promoting or antagonizing, 
respectively, cellular proliferation and survival, stability genes act to maintain genomic 
integrity through prevention of chromosomal instability and repair of damaged DNA.  The 
process of tumor formation is induced by reactivation, constitutive activation, or 
amplification of oncogenes, coupled with inactivation of tumor suppressor and stability genes.  
Such alterations in gene expression can result from direct genomic mutation, from epigenetic 
events, which alter gene expression without affecting the primary DNA sequence, i.e. by 
promoter methylation, or from defects in the control of mRNA or protein stability, i.e. by 
microRNAs or ubiquitination (Alvarez-Garcia and Miska, 2005; Baylin and Ohm, 2006; 
Devoy et al., 2005; Hall and Russell, 2005).   
 
Tumor suppressor loci, such as those of the transcription factor p53, the CDK 
inhibitor p27Kip1/Cip1, or the lipid phosphatase PTEN, can be haploinsufficient for tumor 
suppression (Cook and McCaw, 2000; Fero et al., 1998; Sulis and Parsons, 2003; 
Venkatachalam et al., 1998), requiring the inactivation of only one allele in order to promote 
tumorigenesis.   In different settings, these and other tumor suppressor genes such as pRb, 
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BRCA1 and BRCA2 have often been characterized as undergoing a “two-hit” mode of 
inactivation, in which a primary inactivating event is followed by loss of heterozygosity 
(LOH), or inactivation of the second allele (Knudson, 1971; Payne and Kemp, 2005; 
Vogelstein and Kinzler, 2004).  Ultimately, the outcome of such genetic alterations is 
dependent on the sequence of their appearance and on the context, at both the micro- and 
macroenvironmental levels, in which they occur. 
 
Context of cancer development 
The contexts in which cancers arise are diverse.  There are more than 100 different 
tumor types, though more than half arise in the lung, prostate, breast, colon, and rectum. 
Each tumor type is distinguishable by a unique microenvironment defined by the specific 
milieu of cell types characteristic of the tissue in which the tumor arises.  Each 
microenvironment is individually governed by interactions between the tumor cells and the 
surrounding stromal cells and extracellular matrix (Bissell and Radisky, 2001). 
 
As the genetic alterations leading to cancer within the different cell types are 
beginning to be elucidated, it is becoming evident that the prevalence of some mutations are 
tumor-type specific.  For example, even though the BRCA1 (Breast Cancer 1) gene product 
appears to be widely required across all cell types to play key roles in homologous 
recombination, inherited BRCA1 mutations have been associated with familial breast and 
ovarian cancers, but not other cancers (Turnbull and Hodgson, 2005).  In addition, somatic 
BRCA1 mutations have not been reported in sporadic breast or ovarian cancers.  This 
paradox has been proposed to be attributable to the weak selective advantage caused by loss 
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of BRCA1, coupled with temporal differences in the sensitivity to such alterations during 
development in different tissues.  Additionally, functional redundancy of signaling pathways 
that compensate for the loss of BRCA1, for example, may protect some cell populations, but 
not those lacking similar safeguards (Sherr, 2004). 
 
The cancers arising from cancer predisposition syndromes are in fact relatively rare.  
Most cancers appear to arise sporadically, and have not revealed overt inheritance patterns.  
It is thought, however, that many low penetrance genes that confer increased cancer 
susceptibility in combination with environmental factors may be contributing to the 
variability of tumor development observed in different individuals.  Such modifier loci have 
yet to be defined in humans, but appear to play an important role in tumorigenesis in mice of 
different genetic backgrounds (Loeb et al., 2003).     
 
Global principles of tumorigenesis 
As increasing numbers of molecular alterations associated with tumorigenesis 
become evident, several global principles guiding the neoplastic process have emerged.  
Given the common molecular machinery governing basic cellular processes of proliferation, 
differentiation, and death across all cell types, such rules are can be broadly applicable.  
Some of the salient traits shared by many human tumors include: self-sufficiency in growth 
signals, insensitivity to anti-growth signals, defective DNA damage/repair pathways and 
genetic instability, evasion of apoptosis, limitless replicative potential (immortalization), 
sustained angiogenesis, and in more advanced malignancies, tissue invasion/metastasis 
(Hahn and Weinberg, 2002; Hanahan and Weinberg, 2000).  Roughly four to seven such 
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rate-limiting events appear to be necessary for cancer development in human cells, and even 
fewer are required in rodent cells (Hanahan and Weinberg, 2000).  Fewer alterations seem to 
be required in the formation of ‘liquid’ (leukemias or lymphomas), versus those required in 
‘solid’ (epithelial or mesenchymal) tumors, partly because of the migratory behavior already 
innate to precursors of liquid tumors (Vogelstein and Kinzler, 2004). 
 
In becoming self-sufficient in growth, the cancer cell loses its reliance on 
extracellular growth factor, mitogenic, and nutrient signals in the microenvironment to grow 
and proliferate.  Their relationship with the surrounding extracellular matrix and 
communications transmitted by cell-cell interaction molecules that normally contribute to 
homeostatic growth often becomes altered (Bianco et al., 2006).  Dysregulation of growth 
factor receptor signaling pathways, which are normally under stringent control, is one of the 
most common alterations in the cancer cell.  Members of the Receptor Protein Tyrosine 
Kinase (RPTK) family, including the EGFR (epidermal growth factor receptor) and InsR 
(insulin receptor) subfamilies, for example, are often dysregulated in cancer, which can 
promote ligand-independent signaling and pathway hyperactivation (Bennasroune et al., 
2004). Alterations of RPTKs commonly observed in cancer include gain-of function 
mutations, genomic rearrangements creating RPTK-containing fusion proteins, or over-
expression resulting from genomic amplification. Mutations in the downstream effectors of 
growth factor receptor signaling are also prevalent. For example, deregulated Ras–Raf–ERK 
or PI3K–AKT–mTOR signaling at multiple points along either pathway commonly 
eliminates the requirement for extrinsic growth factor stimulation (Blume-Jensen and Hunter, 
2001). 
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Cancer cells must also be able to evade anti-growth signals to maintain continued 
growth.  Anti-growth signaling normally disrupts active proliferation by driving cells into a 
quiescent (G0) state, or into a post-mitotic, terminally differentiated state.  These states are 
largely governed by signaling that regulates the cell division cycle or cell growth, i.e. the pRb 
pathway or the Myc pathway, and are consequently frequent targets in cancer (Sherr, 2004). 
 
Since the measured rate of mutation in human cells is lower than that deduced from 
the natural occurrence of neoplastic growth observed in the general population, the 
development of cancer cells is presumably hastened by the acquisition of a ‘mutator’ 
phenotype (Loeb, 1991).  A mutator phenotype most often stems from mutations in 
‘caretaker’ genes responsible for monitoring genomic integrity, repairing damaged DNA, and 
ensuring proper chromosomal segregation during mitosis (Raptis and Bapat, 2006). The 
inability to repair double stranded breaks in DNA, for example, and failure to trigger an 
appropriate mitotic checkpoint to arrest growth under such conditions, can lead to gross 
chromosomal changes such as translocations or amplifications, leading to chromosomal 
instability, and more rapid accumulation of further genetic alterations. 
 
With normal cellular checkpoints in place, the occurrence of such oncogenic events 
as malfunctioning cellular networks and genomic instability would normally trigger an innate 
tumor suppressor response involving proliferative arrest and often programmed cell death or 
apoptosis.  Cancer cells therefore must acquire the ability to circumvent such checkpoints.  
Once apoptosis is activated by extrinsic (i.e., TNF and FAS) and intrinsic signals (a balance 
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of pro- and anti- apoptotic BH3-containing family of proteins, i.e., Bax and Bcl-2), the 
cleavage of a cascade of caspases is activated, which drive the destruction of the cell (Fadeel 
and Orrenius, 2005).  Cancer cells become resistant to apoptosis through a variety of 
mechanisms, the most common of which is the inactivation of the p53 tumor suppressor 
pathway. p53 is a master regulator of the cellular response to stresses such as hypoxia, 
nutrient deprivation, DNA damage, and oncogene hyper-activation. By disrupting the p53 
pathway, a cell presented with such stresses fails to initiate pro-apoptotic signals such as 
activation of Bax, or mitochondrial cytochrome c release, resulting in predomination of 
survival signaling (Klein and Vassilev, 2004). 
 
When confronted with dyregulated signaling and growth, most mammalian cells have 
another mechanism, termed senescence, to autonomously block further growth. The normal 
cellular senescence program causes irreversible cell-cycle arrest accompanied by epigenetic 
changes in chromatin and altered cell morphology.  As cells normally age, chromosome 
ends—telomeres, progressively shorten in length, eventually leading to (replicative) 
senescence.  Senescence can also be triggered in response to oncogenic or genotoxic stress, 
as has been observed in response to Ras activation (Serrano et al., 1997). Senescence, like 
apoptosis, therefore represents an internal tumor suppressor mechanism in place that limits 
replicative potential and oncogenic transformation (Lowe et al., 2004).  If the pRb or p53 
pathways are disrupted, however, the senescence program can be circumvented.  The 
resulting progressive shortening of telomeres can lead to fusion of unprotected chromosome 
ends, chromosomal instability, and entry into ‘crisis’.  Variants that can emerge from the 
crisis state exhibit activation of telomerase (hTERT) or have utilized recombination-based 
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interchromosomal exchange pathways to restore telomere length, so that an immortalized cell 
with even greater oncogenic potential persists (Blasco, 2005; Dimri, 2005). 
 
Given the ability to proliferate limitlessly, tumors will be incapable of growing to 
large sizes (greater than 2 mm in diameter) unless provided with a sustained blood supply for 
exchange of nutrients, oxygen, and metabolic waste. Oxygen deprivation in the tumor 
microenvironment activates the expression of HIF1 (Hypoxia Inducible Factor 1), which can 
contribute to the expression and secretion of stimulatory growth factors and cytokines that 
recruit endothelial and stromal cells, and allow angiogenesis—the development of new blood 
vessels, for the growing neoplasm (Kaelin, 2005).  VEGF (vascular endothelial growth factor) 
and FGF (basic fibroblast growth factor) serve as such angiogenic factors, and are frequently 
over-expressed in cancer (Carmeliet, 2005). 
 
Tumors often remain benign if their growth is constrained within their tissue of origin, 
but can become malignant once they have acquired the capacity to invade other tissues and 
metastasize to and proliferate in distant sites.  Metastastic tumors in fact account for the vast 
majority of cancer patient deaths (Sporn, 1996).  The ability of metastatic tumor cells to 
mobilize through and invade a variety of tissues is not well understood molecularly, but 
appears to be driven by altered interactions with extracellular matrix components and the 
microenvironment, activation of extracellular proteases, and epithelial-mesenchymal 
transition (EMT), a process whereby epithelial cells acquire mesenchymal, fibroblast-like 
properties and show reduced intercellular adhesion and increased motility.  EMT and 
metastasis have been demonstrated to be linked to several oncogenic pathways involving Ras, 
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integrins, Wnt/beta-catenin, and PI3K/ AKT, coupled with down-regulation of the cell 
adhesion molecule E-cadherin (Larue and Bellacosa, 2005; Wittekind and Neid, 2005). 
 
Signaling pathways commonly altered in cancer 
As the signaling pathways driving these global principles of cancer progression are 
becoming better defined, their recurrent involvement across many different tumor types is 
becoming more evident.  Several pathways, some of which were highlighted above, have 
been defined as critical targets in tumorigenesis, and include the p53, pRb, PI3K, RTKs, 
TGFß / SMAD, Bcl/apoptotis, APC (Adenomatous polyposis coli)/ ß-catenin, Hedgehog/ Gli 
(glioma-associated oncogene), and HIF1/ hypoxia pathways (Vogelstein and Kinzler, 2004).  
Many of these pathways are commonly found to be co-opted by viruses to drive malignancies; 
for example, the large T antigen expressed by the SV40 DNA tumor virus promotes 
tumorigenesis by disrupting both the pRb and p53 pathways.   
 
The pathways listed above govern a wide array of biological processes, including the 
cell division cycle, cell growth, metabolism, DNA repair, survival, apoptosis, development, 
and differentiation (Bianco et al., 2006).  Several of these pathways applicable to the studies 
described herein are illustrated in Figure 1.1.  The identification and circuitry of these 
pathways have been pieced together in the study of normal cellular processes, with important 
contributions from biochemical studies in mammalian cells, coupled with seminal genetic 
studies in model organisms such as the fruit fly Drosophila melanogaster and the budding 
yeast Saccharomyces cerevisiae (Hiesinger and Hassan, 2005; Oliver, 2006; Sprinzak and 
Elowitz, 2005; Vidal and Cagan, 2006). 
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As the gene products that comprise these signaling pathways are better characterized, 
an ‘exclusivity principle’ of pathway disruption in cancer has become clearer, and dictates 
that a single alteration within a given signaling pathway is sufficient to promote 
tumorigenesis.  The p53 pathway, for example, has been demonstrated to be inactivated in 
most, if not all, human tumors (Levine, 1997).  In different settings, the p53 pathway has 
been found to be inactivated by direct mutation of the p53 gene, over-expression of the p53 
antogonist HDM2 (an E3 ubiquitin ligase), or inactivation of the HDM2 antagonist, p19ARF, 
but not by more than one of these events in a single tumor.  Such an exclusivity principle has 
been found to be broadly applicable across known cellular pathways (Sherr, 2004). 
 
The cell division cycle and cell growth 
 
 The balanced growth of a cell, and its equal division into two daughter cells, are 
highly regulated processes governed by conserved signaling pathways that have been well 
characterized (Mitchison, 2003; Sherr and McCormick, 2002). 
 
Cyclins, CDKs,  retinoblastoma (pRb), and the cell cycle 
The pRb pathway is a central point of convergence of signaling that governs the cell 
division cycle: the ordered set of events that results in DNA replication, cell growth, and 
division into two daughter cells (Sherr and McCormick, 2002).  The pRb pathway regulates 
entry into and transition through the first gap phase (G1) of the cell cycle (Figure 1.1).  The 
G1 phase serves as a critical period in which many signals coalesce to control proliferation 
and differentiation.  It is not surprising then that disruption of the pRb pathway, which would 
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permit unrestrained passage through this most important transition of the cell cycle, is one of 
the most frequently encountered events in cancer.  The pRb protein is part of a family that 
includes p107 and p130.  During G1, the pRb family proteins act to inhibit entry into the 
DNA synthesis (S) phase of the cell cycle, primarily by binding to and inhibiting the E2F 
family of transcription factors.  As the cell cycle progresses, the pRb proteins lose their 
ability to repress E2Fs due to inactivating phosphorylation events driven by cyclin dependent 
kinases (CDKs), allowing expression of E2F responsive genes required for DNA synthesis. 
CDKs are positively regulated by their cyclin binding partners, whose levels fluctuate 
throughout the cell cycle—increasing upon induction by mitogenic signaling, and decreasing 
again rapidly by targeted degradation.  CDK4 and CDK6 bind D-type cyclins, and CDK2 
binds E-type cyclins; once activated, CDK4/6 and CDK2 act sequentially to phosphorylate 
and disable the pRb family proteins.  CDK4/6 are inactivated by the INK4 (inhibitors of 
CDK4: p15 INK4b, p16 INK4a, p18 INK4c, p19 INK4d) and Cip/Kip (p21Cip1, p27 Kip1, p57 Kip2) 
families of CDK inhibitors.  The pRb pathway has been found to be altered in cancer by 
disruption of p16INK4a or of pRb itself, by over-expression of cyclin D or cyclin E, or by 
constitutive activation of CDK4, but never by more than one of these alterations, since the 
functional consequence of any one of these events is similar (Sherr, 2004).  
  
 Genetic analyses in mice provide further evidence for the importance of the pRb 
pathway in tumor suppression.  Mutations disrupting D-type cyclins or CDK4 inhibit 
oncogenic signaling and tumor development (Malumbres and Barbacid, 2006).  Similarly, 
inactivating mutations of Rb, INK4a, INK4c, or constitutive activation of CDK4 (Mittnacht, 
2005) resulted in the development of many tumor types in mice.  Since disruption of the pRb 
pathway is often necessary for neoplastic progression, insight into the function and regulation 
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of the components of this pathway will advance our understanding of cancer development, 
and therefore guided the focus of the studies described in chapters IV and V.   
 
Given the vulnerability of cells to tumorigenesis upon disruption of the pRb pathway, 
strict mechanisms have evolved to control entry and progression through the cell cycle.  
Strict controls are also in place to regulate cell growth (increase in cell mass), which must be 
coordinately regulated with the cell cycle to maintain cell size within physiological limits.  
Although the term ‘growth’ is often used interchangeably with ‘proliferation’ or in describing 
cell cycle progression, growth and the cell cycle are in fact distinct, separable processes.  
Stable proliferation results from a coordinate balance between growth and cell cycle 
progression.  If uncoupled, i.e. if the cell cycle and cell division proceeded in the absence of 
cell growth, progressively smaller daughter cells would result, while conversely, cell growth 
in the absence of cell division can lead to cellular hyperplasia (Mitchison, 2003). 
 
 Gene expression microarray analysis of neoplastic versus normal cell counterparts 
almost invariably exhibit up-regulation of genes not only controlling the cell cycle, but also 
those that regulate cell growth.  Such an expression profile, referred to as a proliferation 
signature, is a strong indicator of poor prognostic outcome in cancer patients (Whitfield et al., 
2006). Although the controls guiding cell growth and cell cycle progression can overlap, they 
can be distinguished as arising from distinct signaling events.     
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Cell growth, mTOR, and the Tuberous Sclerosis Complex (TSC) 
 
Cell growth in metazoan cells is regulated in large part by the well-conserved PI3K/ 
AKT/ TOR signaling pathway (Figure 1.1).  The lipid kinase PI3K (phosphoinostide 3-kinase) 
is activated by growth factor signaling, such as through insulin growth factor receptor (IGFR, 
a RTK) activation by extracellular insulin-like growth factors.  Activated PI3K generates 
phosphatidylinositol-3,4,5-trisphosphate (PI(3, 4, 5)P3), which serves as a second messenger 
essential for activation of AKT (PKB, protein kinase B).  PI3K activity is antagonized by the 
lipid phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) 
(Parsons, 2004; Sansal and Sellers, 2004). 
 
Central to the growth signaling pathway is the mammalian Target of Rapamycin 
(mTOR or TOR) serine/threonine kinase that, as its name indicates, is inhibited by rapamycin, 
a clinically important drug used as an immunosuppressant, an anti-fungal, and as a potential 
anti-cancer drug (Georgakis and Younes, 2006). mTOR assembles with the scaffolding 
molecule raptor and GßL to form a functionally distinct complex, mTORC1, which is 
rapamycin-sensitive, while an alternative complex, mTORC2, composed of mTOR, rictor 
and GßL, is rapamycin-insensitive.  mTORC1 regulates ribosomal biogenesis and mRNA 
translational control primarily through phosphorylation of its downstream substrates/ 
effectors, S6K (ribosomal S6 kinase 1) and 4EBP1 (eukaryotic initiation factor 4E binding 
protein 1).  TOR is positively regulated by Rheb, that itself is negatively regulated by the 
tuberous sclerosis complex gene products, TSC1 (hamartin) and TSC2 (tuberin).  TSC2 is a 
GAP (GTPase activating protein) that directly inactivates the small GTPase Rheb 
(Kwiatkowski and Manning, 2005; Nobukini and Thomas, 2004). 
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TSC2 and TSC1 physically bind and stabilize one another as a heterodimer.  TSC1 
and TSC2 were originally identified as tumor suppressor genes disrupted in the autosomal-
dominant disorder, tuberous sclerosis complex (TSC), which is diagnosed in roughly 1 in 
6,000 newborns.  Mutations in either TSC1 or TSC2 can account for TSC, though TSC2 
mutations are more prevalent.  TSC is characterized by the development of hamartomas, 
which are tumorlike malformations that are typically benign, and frequently result from loss 
of heterozygosity of the remaining wild type TSC1 or TSC2 allele, and subsequent 
dysregulation of growth and development (Astrinidis and Henske, 2005).  Hamartomas of 
TSC patients have been found to develop in a number of different tissues, including the brain, 
kidneys, skin, heart, and lungs. The severity of the TSC disease is typically dependent on the 
location at which the hamartomas arise.  TSC patients can experience relatively mild 
symptoms, such as facial angiofibromas, to more severe manifestations, such as development 
of renal cysts and renal cell carcinoma, or development of cerebral cortical tubers, which can 
cause of seizures, mental retardation, and autism (Consortium, 1993; Roach et al., 1998). 
 
 
The in vivo function of TSC1-TSC2 have recently been elucidated by studies in D. 
melanogaster that identified the TSC genes (dTSC1 and dTSC2) as important regulators of 
cell growth (Pan et al., 2004), which was reinforced by multiple studies in mammalian cells 
(Inoki et al., 2005b).  As a complex, TSC1-TSC2 has been found to serve as a central node 
within the growth signaling pathway, integrating signals from growth factors, nutrients, stress, 
and cellular energy levels (Inoki et al., 2005b).  TSC1-TSC2 receives inputs from at least 
three major signaling pathways, including the PI3K-AKT pathway, the ERK1/2-RSK1 
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pathway and the LKB1-AMPK pathway (Kwiatkowski and Manning, 2005).  Growth factor 
signaling via the PI3K-AKT pathway or the MAPK-ERK-RSK1 pathway can act to disable 
the TSC complex, through direct phosphorylation of TSC2 by AKT, or by ERK1/2 or RSK1.  
The LKB1-AMPK pathway senses fluctuations in cellular energy levels (i.e., ATP and AMP 
levels); under energy-starved conditions, the TSC complex is activated by direct 
phosphorylation of TSC2 by AMPK (Hardie, 2005).  Therefore, mutations that alter TSC1 or 
TSC2 result in the disruption of a central node of regulation of the cell growth pathway. 
 
Many of the proteins that promote cell growth and are known to be activated in 
cancer (PI3K and AKT) are classified as oncoproteins, and conversely, the proteins that 
restrict cell growth and are inactivated in neoplastic events (i.e., PTEN, TSC1 and TSC2) are 
commonly labeled as tumor suppressors (Inoki et al., 2005a), emphasizing the importance of 
cell growth regulators in tumorigenesis.   
 
 
 
The ubiquitin—proteasome system 
 
Many biological processes, such as cell cycle progression and proper developmental 
control, are dependent on the regulated rise and fall in gene expression.  This control can be 
mediated by a number of mechanisms, one of which involves regulated proteolysis.  The 
ubiquitin-proteasome pathway is the predominant cellular pathway controlling regulated 
protein destruction across nearly every aspect of eukaryotic cell biology, and not surprisingly, 
is commonly dysregulated in cancer (Yamasaki and Pagano, 2004).  The von Hippel-Lindau 
(VHL) syndrome, for example, is a cancer predisposition system resulting from mutations in 
the VHL gene, whose normal gene product serves to ubiquitinate the pro-angiogenic 
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transcription factor, HIF1α, marking it for degradation.  Loss of VHL function in VHL 
patients or by sporadic inactivation in somatic cells results in stabilization of HIF1α, and 
predisposition to a variety of highly vascularized tumors (Kaelin, 2002). 
 
The regulatory modification of cellular proteins by ubiquitination has been found to 
be dysregulated in a number of different oncogenic settings, affecting a wide array of 
substrate proteins (Fig. 1.2).  For example, in colorectal cancer, the APC gene is frequently 
mutated, which prevents the oncoprotein transcription factor beta-catenin from being 
phosphorylated and targeted for ubiquitination, leading to its accumulation (Xiong and 
Kotake, 2006).  Cervical cancer most often results from infection by the human papilloma 
virus.  One of its proteins, E6, hijacks the cellular ubiquitination machinery to target the 
tumor suppressor protein p53 for degradation (Mantovani and Banks, 1999).  In familial 
cases of breast cancers, the BRCA1 gene is often mutated; BRCA1 is in fact thought to be 
involved in ubiquitinating cellular proteins involved in chromosomal stability (Starita and 
Parvin, 2006).  In a number of other cancers, the oncoproteins HDM2 or Skp2 are 
constitutively activated or over-expressed, leading to destruction of the tumor suppressor p53, 
or the CDK inhibitor p27, respectively (Burger and Seth, 2004; Mani and Gelmann, 2005; 
Pagano and Benmaamar, 2003). 
 
Ubiquitin-mediated proteolysis is a multi-step process, and requires three sequential 
enzymatic activities supplied by E1 (ubiquitin activating), E2 (ubiquitin conjugating) and E3 
(ubiquitin ligating) enzymes (Figure 1.2; Hershko and Ciechanover, 1998).  The process of 
ubiquitination initiates with formation of an ATP-dependent thio-ester bond between 
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ubiquitin (an 8.6 kDa protein) and the E1 enzyme.  Activated ubiquitin is then transferred to 
an E2.  An E3 ubiquitin ligase largely determines the specificity of the reaction, in that it is 
responsible for recruiting the substrate and mediating the transfer of the ubiquitin from the 
E2 to the substrate.  The substrate becomes bound by ubiquitin through an isopeptide linkage 
on one or multiple lysine residues, and can subsequently undergo multiple rounds of 
ubiquitination, leading to the formation of polyubiquitin chain(s).  Polyubiquitinated proteins 
are typically rapidly delivered to and degraded by the 26S proteasome, a 2.5 MDa multi-
subunit complex (Pickart, 2001).  Polyubiquitin chains linked through lysine residue 48 of 
ubiquitin (K48) to substrates commonly mark these proteins for destruction by the 
proteasome.  Ubiquitin linked through K63 to a substrate, often resulting in a 
monoubiquitinated protein, does not result in proteasome-dependent destruction, but rather 
can play important signaling roles affecting protein localization and DNA repair (Haglund 
and Dikic, 2005; Sun and Chen, 2004).  
 
E3 ubiquitin ligase families 
The large array of proteins targeted by ubiquitin ligases is matched by a diverse array 
of E3s, which can be categorized into two large families.  The HECT family of E3s is 
characterized by the HECT domain, homologous to the E6AP carboxyl terminus, and is 
functionally distinct in its ability to directly form thioester linkages with ubiquitin (Ardley 
and Robinson, 2005; Huibregtse et al., 1995).  The RING family of E3s contains either an 
intrinsic RING finger domain or an associated RING subunit essential for their ubiquitin 
ligase activity that does not form a direct thioester linkage with ubiquitin, but mediates the 
transfer of ubiquitin from the E2 to substrate (Deshaies, 1999). 
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Cullin-dependent ubiquitin ligases belong to the RING family of E3s.  The cullins are 
a well-conserved family of genes that in mammals include CUL1, CUL2, CUL3, CUL4A, 
CUL4B and CUL5, and three related genes (CUL7, Parc and APC2).  Cullins serve as 
scaffolding molecules that assemble multi-subunit E3 ligases (Petroski and Deshaies, 2005).  
CUL1 is the best-characterized of the Cullins, and the SCF (Skp-CUL1-F-Box) complex, 
whose crystal structure has been solved (Figure 1.2; Zheng et al., 2002b), is seen as the 
prototype of Cullin complexes.  A highly conserved domain within the C-terminus of CUL1 
is required for its association with the RING finger protein ROC1 (RING of cullins) (also 
known as Rbx1 and Hrt1).  CUL2, CUL3, and CUL4 also associate with ROC1, while CUL5 
preferentially associate with ROC2, a ROC1 paralogue (Donaldson et al., 2004; Kamura et 
al., 2004).  ROCs recruits and allosterically activates an E2 ubiquitin conjugating enzyme, 
forming the catalytic core of the complex (Joazeiro and Weissman, 2000; Ohta et al., 1999; 
Seol et al., 1999). 
 
The N-terminal region of Cullins is the most variable, and therefore not surprisingly 
serves as the region that determines substrate specificity.  The N-terminus of CUL1 is 
necessary for binding to SKP1, an “adaptor protein”.  SKP1 in turn serves to bridge CUL1 to 
a “substrate-targeting molecule,” an F-box protein, which directly binds phosphorylated 
substrate (Jackson et al., 2000; Joazeiro and Weissman, 2000).   Once fully assembled, the 
SCF complex brings substrates into close range of the ROC-E2 catalytic core, promoting 
regulated substrate polyubiquitination. The Drosophila genome contains three ROC genes, 
ROC1A, ROC1B, and ROC2.  Recent genetic studies in Drosophila indicate that the identity 
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of the ROC protein associated with the SCF may functionally distinguish its activity in vivo, 
thereby adding another level of specificity to the complex (Donaldson et al., 2004; 
Noureddine et al., 2002). 
 
Other Cullin family members have been shown to form analogous complexes (Figure 
1.3), though the specific array of subunits of each complex are likely unique to each Cullin.  
CUL2, for example, binds directly to a heterodimeric complex containing Elongin C, a 
SKP1-related protein, which binds a SOCS-box protein (for example, VHL, von Hippel-
Lindau), which in turn associates with substrates such as HIF1α (Lisztwan et al., 1999; 
Maxwell et al., 1999; Ohh et al., 2000).  CUL3 associates with BTB proteins, which then 
directly bind substrate molecules (Furukawa et al., 2003; Geyer et al., 2003; Pintard et al., 
2003; Xu et al., 2003).  Cullins 4, 5, 7 and Parc are much less understood.  Evidence that 
CUL5, like CUL2, associates with Elongins B and C, is becoming clearer, as is the 
distinction between ligase specificity deriving from preferential association with ROC2 
versus ROC1, which dictate different subsets of BC-box interacting proteins as substrate 
specificity factors (Donaldson et al., 2004; Kamura et al., 2004).  CUL4A does not bind to 
either SKP1 or Elongin C (Kamura et al., 1999; Michel and Xiong, 1998), but does associate 
with DDB1 (Damaged DNA Binding Protein 1) (Shiyanov, 1999; (Groisman et al., 2003; Liu 
et al., 2003; Shiyanov et al., 1999; Ulane and Horvath, 2002; Ulane et al., 2003; Wertz et al., 
2004), a strong candidate adaptor protein.   
 
Regulation of cullin complexes by NEDD8, the COP9 signalosome, and CAND1 
All cullins are covalently modified by a small ubiquitin-like protein, NEDD8 
(neuronally expressed developmentally downregulated) through a process termed 
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neddylation (Hori et al., 1999; Lammer et al., 1998; Osaka et al., 1998).  NEDD8 forms an 
isopeptide bond between its C-terminal glycine, and a conserved Cullin lysine residue (Osaka 
et al., 1998).  Cullins are the only identified substrates of NEDD8, and require the association 
of ROC1 or ROC2 to be modified by NEDD8 (Furukawa et al., 2000).  Modification by 
NEDD8 appears to be necessary for normal Cullin function.  Neddylation has been shown to 
be necessary for activation of CUL1, CUL2, CUL3, and CUL4 E3 ligases (Furukawa et al., 
2000; Morimoto et al., 2000; Morimoto et al., 2003; Osaka et al., 1998; Osaka et al., 2000; 
Podust et al., 2000; Read et al., 2000) for facilitating the recruitment of E2 enzymes 
(Kawakami et al., 2001), and thereby promoting polyubiquitination (Wu et al., 2000; Wu et 
al., 2002). 
 
The removal of NEDD8 from Cullins can be accomplished by the COP9 signalosome 
(CSN) (Lyapina et al., 2001; Mundt et al., 2002; Schwechheimer and Calderon Villalobos, 
2004; Zhou et al., 2001; Zhou et al., 2003).  The CSN is a large complex consisting of 8 core 
subunits that was first identified in Arabidopsis as being required for photomorphogenesis           
(Wei et al., 1994).  It is evolutionarily conserved in other plants, fungi, worms, flies, and 
humans, and has since been implicated in a wide variety of biological processes such as 
development, DNA repair, and cell-cell communication (Chamovitz et al., 1996; Freilich et 
al., 1999; Wei and Deng, 2003; Wei et al., 1994).  The CSN is not only associated with 
deneddylase activity, but also with kinase and with deubiquitinating activities.  The CSN- 
associated kinase activity phosphorylates a number of transcription factors including c-jun 
and p53 (Bech-Otschir et al., 2001; Bech-Otschir et al., 2002; Seeger et al., 2001; Seeger et 
al., 1998).  Additionally, the CSN suppresses the autoubiquitination activity of bound Cullin 
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complexes; this activity has been attributed to the CSN5 subunit (Groisman et al., 2003), and 
to Ubp12, a deubiquitinating enzyme that associates with the CSN (Zhou et al., 2003).   The 
CSN is therefore important in both the assembly and stability of cullin complexes (Lyapina et 
al., 2001).  The CSN has been reported to co-purify with the S. pombe CUL4 orthologue, 
Pcu4, and Csn1 and Csn2 were both found to be required for CUL4 function (Liu et al., 
2003).  Human CUL4 complexes have also been shown to co-purify with the CSN 
(Groisman et al., 2003; Liu et al., 2003). 
 
 Cullins are additionally regulated by binding with CAND1 (cullin associated, 
NEDD8 dissociated protein).  CAND1 forms a tight association with both the N- and C- 
terminal domains of cullins, as determined biochemically, and recently confirmed by the 
solved crystal structure (Goldenberg et al., 2004; Hwang et al., 2003; Liu et al., 2002; Lo and 
Hannink, 2006; Min et al., 2003; Min et al., 2005; Oshikawa et al., 2003; Zheng et al., 2002a).  
The ternary complex of CUL1, ROC1, and CAND1 prevents the binding of SKP1, and 
thereby inhibits SCF ligase activity. Data from our lab supports a model in which CAND1 
negatively regulates the assembly of active ligase complexes by preventing association 
between a Cullin its adaptor molecule. Concomitantly, CAND1 regulation of Cullins may 
prevent complex instability by inhibiting inappropriate autoubiquitination of the complex 
(Galan and Peter, 1999; Zhou and Howley, 1998).   Binding of CAND1 is alleviated by 
neddylation of CUL1, allowing the rapid assembly of the SCF ligase into an active complex.  
Through coordinated activities of NEDD8, CAND1 and the CSN, Cullin E3 ligases may 
cycle through multiple rounds of assembly and disassembly (Cope and Deshaies, 2003; Liu 
et al., 2002).   
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Composition of a CUL4-DDB complex and its link to cancer 
CUL4 is of particular interest amongst the cullin family because the CUL4A gene has 
been found to be amplified in primary breast tumors, primary hepatocellular carcinomas, and 
primary esophageal squamous carcinoma (Chen et al., 1998; Yasui et al., 2002), and 
therefore may impose oncogenic activity that contributes to cancer development.  However, 
unlike its well-characterized homologues CUL1 and CUL2, little is known about the in vivo 
functions of CUL4 or the multisubunit complexes formed by CUL4, and were therefore a 
major focus of the studies described in chapters II and III. 
 
It is established that CUL4 interacts with ROC1 in mammalian cells, and ROC1a in 
Drosophila cells (Donaldson et al., 2004; Ohta et al., 1999).  There is also accumulating 
evidence that CUL4 interacts with DDB1, the Damaged DNA binding protein 1.  DDB1 
forms a heterodimer with another subunit, DDB2, in mammalian cells.  The DDB complex 
binds tightly to UV-irradiated DNA (Tang and Chu, 2002), and mutations in DDB2 give rise 
to the cancer predisposition syndrome, Xeroderma Pigmentosum- group E (XP-E) (Cleaver, 
2005).  DDB1 has co-purified with CUL4 in S. pombe (Liu et al., 2003), in HeLa cells 
(Groisman et al., 2003), and in 293T cells, in association with the paramyxovirus V protein 
(Li et al., 2006b; Lin et al., 1998; Precious et al., 2005; Ulane and Horvath, 2002; Ulane et al., 
2003).  A CUL4-DDB1 complex has also been described which additionally associates with 
COP1 (constitutively photomorphogenic-1), and DET1 (de-etiolated 1) as substrate 
specificity factors (Wertz et al., 2004). 
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It has been unclear, though, whether DDB1 and DDB2 act as components of the 
CUL4 E3 ligase, or whether they simply represent direct substrates of CUL4, since 
ubiquitination of both DDB1 and DDB2 is induced by CUL4 (Chen et al., 2001; Galan and 
Peter, 1999; Nag et al., 2001; Zhou and Howley, 1998).  An identifiable DDB2 orthologue 
has not been found in lower organisms, but DDB1 is well-conserved, with close orthologues 
identified in plants, worms, flies, and fission yeast.  Interestingly, in S. pombe, accumulation 
of a replication inhibitor, Spd1, can result from disrupting either DDB1, or the CUL4 
orthologue, Pcu4, or components of the CSN (Bondar et al., 2004; Liu et al., 2003).  In 
addition, human CUL4A interacts stoichiometrically with DDB1, and DDB1 is required for 
UV-dependent degradation of the known CUL4A/B substrate CDT1 (Hu et al., 2004).  
Therefore, we expected that CUL4 targets a number of proteins for ubiquitination through a 
multi-subunit complex containing DDB1 as an adaptor molecule. 
 
A number of proteins containing WD-40 protein: protein interaction domains, 
including DDB2, CSA, COP1, KIAA0800, PWP1, and WDR23 interact with both DDB1 and 
CUL4A (Groisman et al., 2003; Wertz et al., 2004).  One prediction of the model in Figure 
1.3C is that other WD-40-containing proteins may also interact with DDB1/CUL4 through 
their WD-40 domains, providing specificity in a manner analogous to the F-box proteins in 
the SCF complex. 
 
CUL4 functions in vivo  
The CUL4 gene is evolutionarily conserved, with a single homologue in S. pombe, C. 
elegans, D. melanogaster, and 2 highly related genes, CUL4A and CUL4B in mammals.  
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CUL4A and CUL4B are 82% identical, making it likely that they rely on similar adaptor 
complexes, and are partially redundant.  Both CUL4A and CUL4B have in fact been shown 
to target the same substrate, CDT1, for degradation (Higa et al., 2003).  Analysis of mRNA 
expression levels indicated that CUL4A and CUL4B transcripts are broadly expressed, and 
can be found in the same tissue (Chen et al., 1998).  However, CUL4A null mice are lethal, 
suggesting that CUL4B cannot compensate for all of the functions carried out by CUL4A (Li 
et al., 2002). 
 
 The Drosophila genome contains a CUL4 orthologue (referred to as CUL4) encoding 
a protein that is 66% identical to CUL4A and 63% identical to CUL4B, but that is more 
distantly related to human CUL1 (29%), CUL2 (26%), CUL3 (34%) and CUL5 (26%).  
There is also a DDB1 orthologue in Drosophila, DDB1 which shares 60 % identity (74% 
similarity) to the human DDB1 protein, and has been proposed to have a role in cell cycle 
and development (Takata et al., 2002; Takata et al., 2004b).  Genetic studies of ROC1a, 
ROC1b, ROC2, NEDD8, CSN4, CSN5, CUL1, and CUL3 mutant alleles in Drosophila 
(Doronkin et al., 2002; Doronkin et al., 2003; Freilich et al., 1999; Noureddine et al., 2002; 
Oron et al., 2002; Ou et al., 2002; Suh et al., 2002) have already contributed significantly to 
our understanding of the complexity of cullin regulation.  These factors offer a unique 
opportunity to examine the in vivo function of CUL4 in cell cycle control, in response to 
DNA damage, and during development. 
 
Genetic studies of cullins in many different model organisms have indicated essential 
roles in cell cycle control and development (Dealy et al., 1999; Feng et al., 1999; Kipreos et 
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al., 1996; Singer et al., 1999; Wang et al., 1999; Willems et al., 1996).  Deletion of the S. 
pombe homologue of CUL4, Pcu4, resulted in cells that were slower growing and elongated 
with decondensed chromosomes, but was not lethal (Osaka et al., 2000).  A null allele of 
CUL4A in mouse caused early embryonic death (before day 7.5) (Li et al., 2002).  CUL4A 
heterozygous mice are haploinsufficient, being observed nearly half as often as expected (Li 
et al., 2002), implying that proper CUL4A expression is important for embryonic 
development.    
 
In vitro studies of mammalian CUL4A have also suggested a role in cell cycle 
progression.  A stable cell line that over-expresses CUL4A failed to arrest at G2-M following 
ionizing radiation (Gupta et al., 2002).  In addition, overexpression of CUL4A in cultured 
myeloid cells promoted proliferation and attenuated differentiation (Li et al., 2003a).  Both 
reports indicated that normally cycling cells were unaffected by overexpression of CUL4A, 
but that overexpression continued to drive the cell cycle in cells that would otherwise be 
arrested.  
 
CUL4, DDB1, and Nucleotide Excision Repair 
CUL4 and DDB1 have recently been implicated in nucleotide excision repair (NER) 
(Groisman et al., 2003).  Two proteins that play critical roles in NER, DDB2 and CSA, were 
found in identical complexes containing CUL4A, DDB1, ROC1, and the CSN.  NER is a 
central cellular defense against DNA damage caused by UV or environmental carcinogens.  
It consists of two pathways: global genomic repair (GGR) and transcription-coupled repair 
(TCR); GGR removes lesions nonspecifically from the entire genome, while TCR 
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preferentially removes lesions from the transcribed strand of expressed genes (Mellon, 2005; 
Reardon and Sancar, 2005; Sancar et al., 2004; Scicchitano and Mellon, 1997).  DDB2, in 
association with DDB1, is recruited to chromatin and binds to UV-damaged DNA, and 
through an unknown mechanism stimulates GGR (Hwang and Chu, 1993; Hwang et al., 1998; 
Tang and Chu, 2002; Tang et al., 2000). 
 
 CSA, on the other hand, is involved in TCR.  CSA is one of the two genes associated 
with Cockayne syndrome (CS), the other being the CSB gene, whose protein has been shown 
to interact directly with the CSA (Henning et al., 1995).  Mutation of either CSA or CSB 
results in Cockayne syndrome, which is characterized by sun hypersensitivity, developmental 
and neurological defects, and premature aging.  Cells lacking either CSA or CSB, if 
subjected to UV damage, accumulate polyubiquitinated RNA polymerase II (Bregman et al., 
1996).  Given that CUL4A assembles with CSA as an TCR-induced E3 ligase, and because 
RNA Pol II has also been found to co-purify with the complex (Groisman et al., 2003), it is 
plausible that CUL4A/DDB1 may be responsible for the ubiquitination of RNA polymerase 
II. 
 
Potential CUL4 substrates involved in development, proliferation, and DNA repair 
 Recent years have seen an emergence of the identity of a number of CUL4 substrates.  
In S. pombe, the replication inhibitor, Spd1, was found to accumulate in Pcu4 or DDB1 
deficient cells (Bondar et al., 2003; Liu et al., 2003).  Though metazoans do not share an 
Spd1 orthologue, other CUL4 substrates have been suggested to be involved in proliferation.  
The replication licensing factor, CDT1, was stabilized upon disruption of CUL4 expression 
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in C. elegans (Zhong et al., 2003), or in Drosophila or mammalian cells (Higa et al., 2003), 
and was shown to be specifically polyubiquitinated by CUL4 in vitro in response to 
ultraviolet or ionizing radiation (Higa et al., 2003; Hu et al., 2004).  CUL4 also seems to play 
a role controlling the activities of a DNA damage recognition protein, XPC (Xeroderma 
Pigmentosum –group C), the DNA damage checkpoint kinase Chk1, and histone H2A 
following DNA damage via monoubiquitination, reinforcing the importance of a CUL4-
DDB1 complex in regulating the cellular response to DNA damage (Kapetanaki et al., 2006; 
Sugasawa et al., 2005; Zhang et al., 2005).  The HOXA9 homeodomain protein has also been 
demonstrated to be polyubiquitinated by CUL4A, resulting in disruption in the ability of 
HOXA9 to promote granulocyte differentiation (Zhang et al., 2003b).  Finally, the 
ubiquitination of the transcription factor, c-jun, was shown to be catalyzed by a novel CUL4 
complex containing DDB1, ROC1, COP1, and DET1 (Wertz et al., 2004). 
 
 These newly described CUL4 substrates have aided in our understanding of the 
pleiotropy of functions controlled by CUL4 and DDB1, guiding our genetic study of the 
CUL4DDB1 E3 ligase in Drosophila, described in chapters II and III.  Chapters IV and V are 
dedicated to the study of another oncogene of interest, cyclin D, and its interaction with the 
tumor suppressor proteins, TSC1 and TSC2. 
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Figure 1.1.  Major cellular signaling networks affected in tumorigenesis Adapted from Clodagh, 2005O’Shea, 2005 
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Figure 1.2.  The ubiquitin-proteasome system and substrates affected in cancer.  
Ubiquitination occurs through a cascade of enzymatic activities: E1, ubiquitin 
activating; E2, ubiquitin conjugating; E3, ubiquitin ligating.  E3 ligases mediate 
much of the specificity of the reaction via recruitment of cellular proteins; recruited 
substrates are then covalently modified by ubiquitin.  The proteins listed here are 
representative examples of proteins whose dysregulated ubiquitination has been 
described in cancer.
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Figure 1.3.  Structure, domains, and complexes of cullin-dependent E3 ligase.
(A) Solved structure of SCF-ROC1 (Zheng, 2002).  CUL1 serves as a molecular scaffold, 
binding SKP1–SKP2 complex at the helical N-terminal domain, and ROC1 at the globular 
C-terminal domain.
(B) H2 and H5 are hydrophobic helical surfaces in the N-terminal region of CUL1 interact 
with SKP1 and SKP2.  Surface residues in the SKP1-SKP2 binding site of CUL1 are 
conserved only in CUL1 orthologues, but not in paralogues; the same is true of the other 
cullins, suggesting that all cullins have a protein-binding site in their NH2-terminal 
regions conferring different specificity for substrate receptor modules.
(C) CUL1 assembles into multiple SCF ligases and ubiquitinates various substrates.  
CUL2 interacts directly with a SKP1-like protein, Elongin C, and indirectly with a BC-
Box proteins that in turn binds with substrates such as HIF1alpha.  CUL5 assembles an 
analogous complex.  CUL3 associates with substrates through just one class of 
intermediary proteins, BTB proteins.  The substrate targeting mechanism of CUL4 is 
thought to function through DDB1 as a substrate receptor molecule, though it is not clear 
if other substrate receptor molecules or adaptor molecules also associate with the CUL4 
complex.
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Summary 
 
CDT1/DUP is an essential replication licensing factor that is degraded at the onset of 
S phase via ubiquitin-mediated proteolysis to ensure that the genome is replicated only once 
per cell cycle. The CUL4DDB1 E3 ubiquitin ligase is necessary for the regulated proteolysis of 
CDT1/DUP after DNA damage, but whether it plays an essential role in the destruction of 
CDT1/DUP at the beginning of S phase is unclear. In order to examine this issue and to 
determine the in vivo function of CUL4DDB1 we isolated and characterized mutations in the 
essential Drosophila Cul4 and Ddb1 genes. Cul4 and Ddb1 null mutants develop until the 1st 
or 2nd larval instar stage, and display phenotypes consistent with a growth defect:  the 
mutant animals can survive for up to 10 days without developing further and fail to 
incorporate BrdU in most cells. We discovered that the previously described piccolo (pic) 
mutations, which cause growth defects affecting adult bristle, tergite, leg, and wing 
development, represent viable, hypomorphic alleles of Ddb1. Clones of Ddb1 null mutant 
cells generated by mitotic recombination in larval imaginal discs are reduced in size relative 
to control clones. Similarly, Cul4 mutant cells grow slowly and are eventually eliminated 
from the imaginal epithelia most likely via competition with phenotypically normal 
neighboring cells. Depletion of either CUL4 or DDB1 in homozygous mutant larvae or by 
RNAi in cultured S2 or HeLa cells results in hyper-accumulation of CDT1/DUP. DDB1 and 
CDT1/DUP were detected in CUL4 immunocomplexes.  However, clones of either Ddb1 or 
Cul4 mutant imaginal cells demonstrated normal CDT1/DUP degradation at the G1-S 
transition, suggesting that CUL4DDB1 is not necessary for cell cycle regulated CDT1/DUP 
degradation and that the observed hyper-accumulation may be due to growth or cell cycle 
arrest. Cul1 mutant clones were also found to degrade CDT1/DUP normally.  However, 
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Roc1a mutant cell clones, in which both CUL4- and CUL1-dependent E3 ubiquitin ligases 
are inactivated, were compromised in degrading CDT1/DUP during S phase. These data 
suggest redundancy between CUL4 and CUL1 E3 ligases in the control of CDT1/DUP 
degradation during the cell cycle. 
 
Introduction 
To maintain genomic integrity, replication of the genome must occur only once 
during the cell cycle.  Replication is therefore a highly regulated process controlled at 
multiple levels (Blow and Dutta, 2005).  During late mitosis/ early G1 phase of the cell cycle, 
a pre-replication complex (pre-RC) assembles on chromatin at origins of DNA replication.  
The core of the pre-RC is the origin recognition complex (ORC), which associates with the 
origin and recruits binding of Cdc6 and CDT1, which in turn facilitate the loading of MCM2-
7 thereby licensing the origin for replication.  Subsequent activation of the MCM2-7 helicase 
allows unwinding of chromosomal DNA, recruitment of DNA polymerases, and progression 
through S phase (Diffley, 2004).  Once replication has initiated, re-replication is prevented 
through various mechanisms that prevent re-assembly of the pre-RC.  Critical among these is 
the inhibition of CDT1 via binding to its negative regulator, geminin, and via ubiquitin-
mediated proteolysis during S phase (Li and Blow, 2005; Nishitani et al., 2001; Saxena and 
Dutta, 2005; Takeda et al., 2005; Thomer et al., 2004). 
 
 Ubiquitination, or the process by which substrate proteins become covalently 
modified by ubiquitin, is carried out by a series of three different enzymes: the E1 ubiquitin-
activating enzyme, the E2 ubiquitin-conjugating enzyme, and the E3 ubiquitin ligase, which 
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mediates the covalent conjugation of ubiquitin to the substrate.  If polyubiquitinated, 
substrate proteins are often targeted for degradation by the 26S proteasome (Pickart, 2004).  
Since E3 ligases are principally responsible for substrate recognition, they provide much of 
the specificity to the ubiquitination reaction. 
 
 Several E3 ligases have been proposed to be involved in the ubiquitination of CDT1 
upon replication initiation.  The SCFSkp2 (Skp1-Cul1-F box) and a CUL4-containing 
ubiquitin ligase have each been linked to the cell cycle-dependent and/or DNA damage-
induced degradation of CDT1 (Higa et al., 2003; Hu et al., 2004; Kondo et al., 2004; Li et al., 
2003b; Liu et al., 2004; Nishitani et al., 2004; Sugimoto et al., 2004; Zhong et al., 2003).  
Although silencing of CUL4 in C. elegans results in massive re-replication of DNA in seam 
cells that can be rescued by reduction in CDT1 levels (Li et al., 2003b), evidence for CUL4-
dependent degradation of CDT1 in higher organisms has only been demonstrated in response 
to genotoxic stress (Higa et al., 2003; Hu et al., 2004).  CUL1 has been proposed to be 
involved in a CDK-dependent mechanism of CDT1 degradation during the cell cycle, and 
Skp2 binds to CDT1 that has been phosphorylated by cyclin-dependent kinases (Li et al., 
2003b; Liu et al., 2004; Sugimoto et al., 2004).  However, CDK-specific phospho-mutants of 
CDT1 are still efficiently degraded during S phase (Takeda et al., 2005; Thomer et al., 2004).  
Therefore, the mechanism by which CDT1 is targeted for timely degradation during each cell 
cycle is still unclear. 
 
 CUL1 and CUL4 belong to an evolutionarily conserved family of proteins known as 
cullins, which act as molecular scaffolds to assemble multi-subunit E3 ubiquitin ligase 
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complexes in vivo.  Cullins share the greatest homology at their C-terminus, where the 
RING-finger proteins ROC1 or ROC2 bind and recruit E2 conjugating enzymes (Donaldson 
et al., 2004; Kamura et al., 1999; Kamura et al., 2004; Ohta et al., 1999; Seol et al., 1999; 
Skowyra et al., 1999).  The N-terminus of cullins is required for substrate recruitment 
through binding of substrate receptor modules.  Different cullins bind different substrate 
receptor modules, and consequently the cullin NH2-terminus is divergent.  CUL4 is of 
particular interest amongst the cullin family in that the CUL4A gene is amplified in primary 
breast tumors, in hepatocellular carcinomas, and in esophageal squamous carcinoma (Chen et 
al., 1998; Yasui et al., 2002), suggesting an oncogenic activity that contributes to cancer 
development.  However, unlike its better-characterized family member CUL1, the multi-
subunit complexes formed by CUL4 are not as completely defined. 
  
There is accumulating evidence from S. pombe and mammalian cells that the 
Damaged DNA Binding protein 1 (DDB1) serves as an adaptor for substrate recruitment by 
the Cul4 E3 ligase (Groisman et al., 2003; Hu et al., 2004; Kulaksiz et al., 2005; Liu et al., 
2003; Shiyanov et al., 1999; Ulane and Horvath, 2002; Wertz et al., 2004).  In mammalian 
cells, a large subset of cellular DDB1 forms a heterodimer with another subunit, DDB2, 
which binds tightly to damaged DNA (Kulaksiz et al., 2005; Sancar et al., 2004; 
Wittschieben and Wood, 2003; Wittschieben et al., 2005).  DDB2 is mutated in individuals 
with Xeroderma Pigmentosum- group E (XP-E), a cancer predisposition disorder caused by a 
defect in the cellular response to DNA damage (Cleaver, 2005).  Complexes containing Cul4, 
DDB1, and DDB2 or CSA (Cockayne Syndrome-A) have been implicated in the regulation 
of nucleotide excision repair (NER) (Groisman et al., 2003). 
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It has been unclear, though, whether DDB1 serves as the only adaptor molecule for 
the Cul4 E3 ligase, and what in vivo functions CUL4-DDB1 may have in metazoans in the 
absence of genotoxic stress.  In order to better characterize the in vivo functions of CUL4 and 
DDB1 and their role in CDT1 degradation, we generated and analyzed Cul4 and Ddb1 
mutants in Drosophila.  Both Cul4 and Ddb1 were found to be essential for development.  
Cul4 and Ddb1 mutants share overlapping phenotypes, including proliferation and growth 
defects and melanotic tumor formation.  Cul4 mutants exhibited more severe proliferation 
defects relative to that of Ddb1 mutants, suggesting that CUL4 utilizes additional adaptor 
molecules besides DDB1 for substrate targeting.  Mutation of CUL4DDB1 does not affect 
CDT1/DUP degradation during the cell cycle.  Interestingly, CDT1/dup was also efficiently 
degraded in the absence of CUL1, but accumulated in Roc1a mutants or when both CUL1 
and CUL4 were disrupted in either fly or human cells, indicating a redundant, well-conserved 
mechanism of CDT1/DUP regulation. 
 
Results 
Isolation and characterization of Drosophila Cul4 mutants 
 The Drosophila genome contains a single Cul4 orthologue encoding a protein that is 
66% identical to human CUL4A and 63% identical to human CUL4B.  There are two P-
element insertion alleles of Drosophila Cul4 publicly available, one (KG02900) located in 
the 5’UTR and one (EP2518) located in the 3’UTR (Fig. 2.1A).   Homozygous Cul4EP2518 
flies are viable, and Cul4KG02900 causes recessive lethality that is reverted after precise 
excision of the KG02900 P-element.  Because Cul4KG02900 is a hypomorph (see below), we 
isolated additional Cul4 alleles by mobilizing the EP2518 P-element and screening for 
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excision mutations that failed to complement the lethality of Cul4KG02900 and therefore likely 
represent new alleles of Cul4.   Three different mutant alleles were identified from 400 
independent excision events: Cul46AP, Cul411L, and Cul411R. All three Cul4 excision mutants 
arrested during development as first instar larvae, either as homozygotes or in trans to each 
other or over the deficiency (Df(2R)CA53) that uncovers Cul4.  The Cul4KG02900 allele is less 
severe, and Cul4KG02900/ Df(2R)CA53 mutants arrest as second instar larvae.  Strikingly, 
although Cul4 mutants display early developmental arrest, they do not die and can survive 
for over 10 days without growing (Fig. 2.3). 
 
 We generated an antibody specifically recognizing the N-terminus of fly CUL4 and 
detected full length CUL4 (Fig. 2.1C) in wild type larvae, but not in homozygous mutants 
Cul46AP, Cul411L, and Cul411R (Fig. 2.1C, lanes 1-3).  Homozygous Cul4KG02900 mutants 
expressed reduced levels of CUL4, although the ratio of neddylated to unneddylated CUL4 
was increased, relative to wild type larvae (Fig. 2.1C).  The specific breakpoints of each 
excision mutant were determined by sequencing and revealed predicted protein C-terminal 
deletions of 18 residues in Cul411L, 65 residues in Cul46AP and 82 residues in Cul411R.  
Truncated proteins corresponding to the predicted molecular weights were detected by 
Western blot in both Cul46AP and Cul411R mutants as single, un-neddylated bands (Fig. 2.1C), 
whose stability could be partially attributable to their inability to be neddylated (Wu et al., 
2005).  The Cul411L allele, which is likely destabilized by the fused P-element sequence, 
resulted in undetectable protein levels by Western blot and appears to be a null allele (Fig. 
2.1C).  All three truncation mutants retain the ROC binding site, but lack the NEDD8 
conjugation site (K767) and a highly conserved C-terminal domain (Fig.. 2.1B), providing in 
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vivo evidence supporting the essential function of NEDD8 conjugation and/ or the C-terminal 
domain of CUL4 (Feldman et al., 1997; Furukawa et al., 2002; Furukawa et al., 2000; 
Kipreos et al., 1996). 
 
Isolation and characterization of Drosophila Ddb1/ piccolo mutants 
 Biochemical analyses using cultured S2 cells demonstrated that as in mammalian 
cells, CUL4 and DDB1 physically interact as assayed by co-immunoprecipitation, either 
when ectopically expressed (Fig. 2.2A), or as endogenous proteins (Fig. 2.2B).  Like Cul4, 
Drosophila Ddb1 is an essential, well-conserved gene, encoding a protein that is 61% 
identical to human DDB1.  Ddb1EY01408, a lethal P-element allele (Fig. 2.2C), causes growth 
arrest developmentally early during second larval instar.  Precise excision of the EY01408 P-
element rescued the lethality of Ddb1EY01408 flies, and imprecise repair of EY01408 excision 
events yielded multiple additional Ddb1 alleles with a range of severity.  The most severe 
Ddb1 alleles caused second instar lethality, while less severe alleles allowed survival until 
third instar or pupal stages.  The least severe Ddb1 alleles resulted in adult flies with reduced 
viability and fertility, and notable growth defects including missing/ thin bristles (Figs. 2.3B, 
C) when compared with wild type flies (Fig. 2.3A). 
  
 Upon scanning the cytological map surrounding the Ddb1 locus on 3R, we 
recognized that a previously defined locus termed piccolo (pic), mapped roughly to a location 
on 3R adjacent to the rosy locus by complementation analyses of 40 previously-generated X-
ray and EMS mutants (Flybase), caused growth abnormalities similar those caused by 
hypomorphic Ddb1 mutants.  Viable piccolo mutants were originally characterized based on 
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shared irregularities in bristle, wing, and tergite growth (Clark and Chovnick, 1986; Hilliker 
et al., 1980; Rushlow and Chovnick, 1984; Schalet et al., 1964).  This type of growth defect, 
manifest in short, thin bristles and delayed development, is reminiscent of phenotypes 
observed in hypomorphic myc (diminuitive) and haploinsufficient ribosomal subunit Minute 
mutants (Lambertsson, 1998; Schreiber-Agus et al., 1997). 
 
 We obtained flies carrying picS026316, picdrv3, and pic2 alleles, and found that they 
caused 2nd (picS026316 and picdrv3) to 3rd (pic2) instar lethality, and failed to complement the 
lethality caused by Ddb1EY01408.  By Western blot, we confirmed that Ddb1EY01408, picS026316, 
and picdrv3 are null Ddb1 alleles, while pic2 is a hypomorphic allele that expresses DDB1 at 
reduced levels (Fig. 2C). The pic2 X-ray allele was sequenced and found to contain a Gly21-
to-Asp substitution in Ddb1, thereby altering a single residue that is positioned at a turn in 
propeller A of the tertiary structure of DDB1 (Li et al., 2006b), and is well conserved across 
species.  Picdrv3 resulted from an uninverted transposition event following UV irradiation 
(Clark and Chovnick, 1986), leaving a large segment of genomic DNA inserted within the 
Ddb1 locus.  Sequence surrounding the SO26316 P-element was available, and corresponded 
to the 5’ UTR of Ddb1 (Flybase; Szeged Stock Center).  The pic2 allele combined with other 
weak Ddb1EY01408 excision alleles resulted in viable flies that were piccolo in phenotype, with 
a subset also afflicted with abnormal wing (Fig. 2.3D) and leg development (data not shown).  
Taken together, these data confirmed that piccolo is in fact Ddb1.  Importantly, Ddb1EY01408, 
picSO26316, picdrv3, and pic2 mutants all phenocopied the early growth arrest with continued 
survival observed in CUL4 mutants (Fig. 3G), suggesting that a CUL4-DDB1-dependent E3 
ubiquitin ligase may control a substrate(s) important in cell growth control. 
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 Another phenotype shared by both Cul4 and Ddb1 mutant larvae is the development 
of melanotic masses/ tumors with varying severity (Figs. 2.3H-J) but high penetrance.  These 
melanotic masses were also detected in hypomorphic Ddb1 mutant adult flies (Figs. 2.3B, D), 
and therefore did not prevent development to adulthood.  Melanotic tumors have previously 
been described as arising in Drosophila larvae in which Ddb1 had been silenced by RNAi 
(Takata et al., 2004a), and are thought to result from abnormal hemocyte development that 
elicits an auto-immune response (Dearolf, 1998; Rizki and Rizki, 1983).   
 
Growth and proliferative defects of Cul4 and Ddb1 mutants 
 To further analyze the consequence of Cul4 or Ddb1 disruption in vivo, we generated 
mutant clones of each via FLP-FRT-mediated mitotic recombination (Xu and Rubin, 1993) 
during larval development.  Larvae were heat-shocked during first instar to induce expression 
of FLP and subsequent mitotic recombination, and wing and eye-antennal discs were 
dissected and analyzed at third instar.  The eye imaginal disc is especially useful in the study 
of cell cycle regulators, since cells within the eye imaginal disc enter a synchronized wave of 
division, in which they arrest in G1 anterior and within the morphogenetic furrow (MF), and 
then undergo a final division, or second mitotic wave (SMW), before differentiating into 
photereceptor cells in the posterior margin.  Cells undergoing S phase within the SMW, or 
within the asynchronously dividing populations anterior to the MF in the eye imaginal disc or 
within wing imaginal discs, were marked by the incorporation of BrdU (Fig. 2.4A).   
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 Under wild type conditions, a twin spot resulting from a single recombination event is 
visible as a patch of GFP positive cells and of GFP negative cells that are roughly equal in 
size, and contain levels of BrdU incorporation that are indistinguishable from other 
surrounding wild type cells (Figs. 2.4A1,2).  In contrast, when Ddb1 mutant clones (GFP-/-) 
were similarly generated, they incorporated BrdU at reduced levels and demonstrated a 1:4 
growth disadvantage relative to wild type clones, in either wing or eye imaginal discs (Figs. 
2.4B, 2.4J).  Cul4 mutant clones, however, were undetectable under the same heat-shocking 
regimen of generating clones (Fig. 2.4D), presumably due to competitive elimination of the 
slower growing mutant cells during larval development.  When recombination was induced 
at late second instar, however, Cul4 mutant clones were visible, but showed reduced BrdU 
incorporation (Fig. 2.4C).   
 
 Proliferative defects resulting from disruption of either Cul4 or Ddb1 were also 
apparent in tissues dissected from mutant larvae.  Hypomorphic Ddb1 mutants (pic2/ 
Ddb1ΔEY01408 transheterozygotes) surviving until third larval instar contained imaginal discs 
that were smaller in size relative to wild type (Figs. 2.4E, F; data not shown), and showed 
irregular/ reduced BrdU incorporation in eye imaginal disc cells within the SMW (Fig. 2.4F).  
We also assessed BrdU incorporation within first instar larval tissues, and observed that 
while cells within wild type brains undergoing S phase were abundant (Fig. 2.4G), reduced 
numbers of BrdU positive cells were found in Ddb1 mutant brains (Fig. 2.4H), and even far 
fewer in Cul4 mutants (Fig. 2.4I).  Indeed, RNAi of CUL4 or DDB1 in S2 cells causes a 
marked G1 arrest (Bjorklund et al., 2006; Higa et al., 2006; Li et al., 2006a). 
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 Collectively, these data indicate that ablation of either CUL4 or DDB1 inhibits 
proliferation and growth.  Cul4 mutant cells, however, appear to be phenotypically more 
severely affected than Ddb1 mutants.  Since CUL4 is more stable than DDB1, having a 
longer half-life than DDB1 (Fig. 2.4K), the milder phenotype observed in DDB1 mutants is 
probably not due to greater perdurance of DDB1 versus CUL4 levels in each respective 
mutant.  Therefore, although CUL4 and DDB1 appear to function in common pathways to 
affect growth, proliferation, and development, CUL4 also potentially has DDB1-independent 
functions. 
 
Involvement of CUL4DDB1 in the regulation of DUP/CDT1 levels 
 A key cell cycle regulator, the replication licensing factor, CDT1/ Double Parked/ 
DUP, had previously been described as being regulated by CUL4 in a subset of cells in C. 
elegans (Zhong et al., 2003), and by CUL4DDB1 following DNA damage (Higa et al., 2003; 
Hu et al., 2004).  We detected DUP in a CUL4 immunocomplex (Fig. 2.2B), and 
unneddylated CUL4 in a DUP immunocomplex (Fig. 2.5D), suggesting that the CUL4DDB1 
E3 ligase may act to regulate DUP protein levels, even in the absence of genotoxic stress. 
 
 To test whether DUP is regulated by CUL4DDB1 in vivo, we carried out 
immunostaining of DUP in imaginal discs in which Cul411L or Ddb1EY01408 mutant clones had 
been generated (Fig. 2.4).  Other substrates have previously been shown to accumulate in 
mitotic clones mutant for components of E3 ubiquitin ligases, indicating the efficacy of such 
an assay in characterizing potential substrates (Jiang and Struhl, 1998; Noureddine et al., 
2002; Ou et al., 2002).  Under wild type conditions, DUP is primarily nuclear, and is most 
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abundant in cells in late mitosis and early G1.  In eye imaginal disc cells, DUP staining is 
pronounced in cells anterior to the SMW, but deficient within the SMW due to degradation 
before the onset of S phase (Fig. 2.3A); (Thomer et al., 2004).  We were surprised to find that 
DUP did not hyper-accumulate in Cul4 or Ddb1 mutant clones (Fig. 2.4).  In fact, DUP 
appeared to be efficiently degraded in these mutants during S phase, as BrdU positive cells 
within Cul4 or Ddb1 mutant clones did not stain positively for DUP, as under wild type 
conditions (Fig. 2.4). This was especially unexpected, since DUP levels were found to be 
elevated in homozygous CUL4 or DDB1 mutants, relative to wild type larvae (Figs. 2.1C, 
2.2D).  Similarly, when CUL4 or DDB1 were silenced by RNAi in S2 or Hela cells, 
respectively, CDT1/DUP levels accumulated modestly (Fig. 2.5D, E).  The observed 
discrepancy in the control of DUP levels in imaginal disc epithilia versus whole mutant 
larvae or S2 cells could be due to differences in the sufficiency of the CUL4DDB1 ligase to 
regulate DUP in different cell types (May et al., 2005; Zhong et al., 2003). 
 
Redundancy in the regulation of DUP by Cullin-dependent E3 ligases 
 Since CUL4DDB1 appeared insufficient in controlling DUP levels, we questioned 
whether other E3 ubiquitin ligases may be required to degrade DUP at the G1-S transition 
during larval development.  CUL1 was also detected in a DUP immunocomplex (Fig. 2.5D), 
indicating that it may be involved in DUP regulation.  To test the potential involvement of 
CUL1 in controlling DUP levels, we generated homozygous null Cul1EX clones, and 
analyzed DUP levels and BrdU incorporation.  In wing or eye imaginal discs containing Cul1 
mutant clones, DUP was detected at normal levels and with normal distribution, showing no 
overlap with cells incorporating BrdU (Fig. 2.5A).   
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 CUL1 and CUL4 independently did not appear to be sufficient to control DUP at the 
G1-S transition during larval development, but might be required to act cooperatively to 
degrade DUP. To test this idea, we generated roc1aG1 clones, in which CUL1-, CUL3-, and 
CUL4-dependent E3 ligases are inactivated (Donaldson et al., 2004).  We positively marked 
roc1a clones with GFP using the MARCM method (Lee and Luo, 2001).  Roc1a mutant 
clones contain few cells, largely due to elimination of roc1a null cells by apoptosis 
(Noureddine et al., 2002).  Although many roc1a clones appeared to degrade DUP normally 
(data not shown), some appeared to accumulate DUP cytoplasmically at greater levels than 
surrounding phenotypically wild type cells (Fig. 2.5B).  Additionally, some roc1a mutant 
cells containing BrdU positive cells also showed elevated DUP levels, compared to 
neighboring GFP negative, BrdU positive cells (Fig. 2.5C).  Similarly, when CUL1 (or SKP2) 
and CUL4 (or DDB1) were co-silenced, versus any protein alone, in HeLa cells, CDT1 levels 
were found to be most hyper-accumulated (Fig. 2.5F).  Interestingly, CUL1 and CUL4 not 
only appear to collaborate functionally, but were also found to interact physically, as detected 
by co-immunoprecipition from S2 cells (Fig. 2.5D) and HeLa cells (unpublished observation, 
C. McCall).  
  
 Since depletion of CUL4 or DDB1 results in arrest in G1 (Bjorklund et al., 2006; 
Higa et al., 2006; Li et al., 2006a), the cell cycle stage at which DUP levels are naturally 
elevated (Nishitani et al., 2001; Thomer et al., 2004), we cannot rule out the possibility that 
the observed hyper-accumulation of DUP was an indirect consequence of the G1 arrest 
caused by disrupted expression of these proteins, rather than a direct effect of inhibited 
ubiquitination and degradation of DUP.  However, given the biochemical evidence of a direct 
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interaction between CDT1/DUP and CUL1 and CUL4 (Figs. 2.1, 2.5) and ubiquitination of 
CDT1/DUP promoted by CUL1- and CUL4- dependent ligases (Hu et al., 2004; Li et al., 
2003b; Liu et al., 2004), the observed hyper-accumulation of DUP in these studies most 
likely represent a direct effect of altered ubiquitination by cullin-dependent E3 ligases. 
 
Discussion 
Cullins have been identified to control critical functions in diverse physiological 
processes, including cell cycle control, gene transcription, the DNA damage response, 
apoptosis, and development (Nakayama and Nakayama, 2005; Petroski and Deshaies, 2005; 
Schwechheimer and Calderon Villalobos, 2004).  Our study demonstrates an essential role 
for CUL4 during the cell cycle, growth, and development in metazoans.  This is in agreement 
with studies from other organisms; a null allele of Cul4A in mice caused early embryonic 
death and was haploinsufficient (Li et al., 2002), and silencing of cul-4 by RNAi in C. 
elegans results in developmental arrest at the L2 larval stage (Zhong et al., 2003).  In vitro 
studies of mammalian CUL4A have also suggested a role in cell cycle progression, as 
overexpression of CUL4A in cultured myeloid cells promoted proliferation and attenuated 
differentiation (Li et al., 2003a).  In S. pombe, although Cul4 (Pcu4) does not appear to be 
essential, its deletion results in elongated, very slow-growing cells with decondensed 
chromosomes (Osaka et al., 2000). 
 
We also provide evidence in support of a role for DDB1 during the cell cycle, growth, 
and development, in the absence of DNA damage.  Previous studies had also indicated that 
silencing of Ddb1 in Drosophila results in early developmental arrest, and that transcription 
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of Ddb1 is controlled by the DRE/DREF system (Takata et al., 2002; Takata et al., 2004b), 
indicating that Ddb1 is a cell cycle-regulated gene.  In S. pombe, like Pcu4 mutants, Ddb1 is 
not essential, and its depletion results in slow-growing, elongated cells with abnormal nuclei 
(Bondar et al., 2003; Bondar et al., 2004; Zolezzi et al., 2002).  Pcu4 and Ddb1 mutants 
exhibit slow S-phase progression, and are incapable of entering premeiotic S phase, largely 
due to accumulation of Spd1, an inhibitor of RNR (ribonucleotide reductase) unique to S. 
pombe (Bondar et al., 2004; Holmberg et al., 2005; Liu et al., 2005; Liu et al., 2003).  It has 
been unknown, though, whether the control of entry into S phase by CUL4DDB1 is 
functionally conserved in higher organisms. 
 
This study demonstrates that CUL4 and DDB1 participate in S phase entry in 
Drosophila, since their disruption inhibited BrdU incorporation in developing larval tissues 
(Figs. 2.4, 2.5).  A key regulator of replication licensing and S phase entry, CDT1/ DUP, is 
under tight control by geminin and ubiquitin-dependent proteolysis, the latter of which in part 
appears to be regulated by CUL4 and DDB1 during normal development (Figs. 2.1, 2.2, 2.5).  
Although CUL4DDB1 appeared insufficient to control DUP at the G1-S phase transition (Fig. 
2.4), these studies revealed redundancy in the replication-dependent proteolysis of 
CDT1/DUP, since the inactivation of both CUL1- and CUL4-dependent E3 ligases by RNAi 
or in Roc1a mutant clones resulted in stabilization of CDT1/ DUP (Fig. 2.5).  This coordinate 
control of DUP appears to be conserved in mammalian cells (Fig. 2.5E).  While this 
manuscript was in preparation, several other studies on the regulated ubiquitination of CDT1 
in Xenopus (Arias and Walter, 2006) and HeLa cells (Nishitani et al., 2006; Senga et al., 
2006) were reported.  The degradation of CDT1 had previously been established to be 
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coupled to the onset of DNA replication (Arias and Walter, 2005; May et al., 2005), and an 
interaction between CUL4DDB1 and PCNA on chromatin appears to trigger CDT1 degradation 
at the G1-S transition, while CUL1-Skp2 appear to principally control CDT1 levels during S-
G2 phases (Arias and Walter, 2006; Nishitani et al., 2006; Senga et al., 2006). 
 
 The importance in controlling CDT1/DUP function during the G1/S transition is 
underscored by the multiple mechanisms in place to limit its activity.  Other examples of 
single substrates controlled by multiple E3 ubiquitin ligases are beginning to emerge, 
including the control of c-jun by CUL4DDB1-based and Itch E3 ligases (Gao et al., 2004; 
Wertz et al., 2004), cubitus interruptus by CUL1- and CUL3-dependent E3 ligases (Ou et al., 
2002),  p53 by MDM2, COP1, Pirh2, TOPORS, ARF-BP1 E3 ligases (Brooks and Gu, 2006).  
Interestingly, CUL1 and CUL4 seem to cooperate in targeting a number of substrates, 
including p27, cyclin E (Higa et al., 2006), and Chk1 (Zhang et al., 2005).  The finding that 
CUL1 and CUL4 co-immunoprecipitate (Fig. 2.5D) suggests that their colocalization in a 
multi-subunit complex may contribute to their cooperative activity in controlling DUP levels. 
 
 Our data also supports the emerging view that DDB1 serves as one but not the only 
adaptor molecule for the CUL4 E3 ubiquitin ligase.  Several recent studies identified Rik1, a 
DDB1-like protein unique to S. pombe, as an adaptor for a CUL4-based E3 ligase that 
regulates Clr4 (Su(var)39) methyltransferase activity to affect methylation of histone H3-K9 
and heterochromatin formation, though the relevant substrate is unknown (Horn et al., 2005; 
Jia et al., 2005; Li et al., 2005; Thon et al., 2005).  DDB1 and Rik1 also share homology with 
other beta-propeller domain-containing proteins, including SAP130 (Splicing and 
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Polyadenylation factor) and CPSF160 (Cleavage and Polyadenylation Specificity Factor) (Li 
et al., 2006b; Neuwald and Poleksic, 2000) which could potentially serve as alternate 
adaptors for the CUL4 complex to affect an even broader array of potential substrates.  
Although CUL4-DDB1 may not require an additional specificity factor to target CDT1 for 
degradation following DNA damage (Hu et al., 2004), the S. pombe Pcu4-Ddb1 complex 
requires the WD-40-containing protein Cdt2 (denticleless) to target Spd1 for degradation 
(Liu et al., 2005), and the Pcu4-Rik1 complex associates with another WD-40 protein, Raf1/ 
Dos1/ Clr8, along with Raf2/ Dos2/ Clr7 to control heterochromatin formation (Horn et al., 
2005; Li et al., 2005; Thon et al., 2005).  In mammalian cells, a complex containing CUL4, 
DDB1, DET1, and the WD-40 protein COP1 assembles to target c-jun for ubiquitination 
(Wertz et al., 2004), and CUL4 and DDB1 have also been described as forming distinct 
complexes with the WD-40 proteins CSA or DDB2 to affect global genomic-NER (and 
ubiquitination of histone H2B) or transcription coupled-NER, respectively (Groisman et al., 
2003; Kapetanaki et al., 2006).  Additionally, the V protein of paramyxoviruses associates 
with the CUL4-DDB1-Roc1 core ligase as an adaptor to target STAT1/2 for degradation 
(Andrejeva et al., 2002; Li et al., 2006b; Lin et al., 1998; Precious et al., 2005; Ulane and 
Horvath, 2002; Ulane et al., 2003). CUL4 therefore appears unique amongst the cullins in the 
diversity of complexes it assembles for substrate targeting. 
 
 The lethality caused by the CUL4 C-terminal truncation mutants isolated in our 
mutagenesis screen (Fig. 2.1) confirm the essential nature of neddylation and/ or the 
conserved C-terminal domain to CUL4 function. Drosophila Cul3 mutants lacking the 
NEDD8 conjugation site (Zhu et al., 2005) or the conserved C-terminal domain (Mistry et al., 
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2004) were also found to be inactive Cul3 alleles, as were similar Cul4 mutants in S. pombe 
(Jia et al., 2005).  We did not recover any excision mutants that ablated the ROC binding site 
within CUL4, which perhaps would have resulted in dominant-negative mutants.   Indeed, a 
Xenopus C-terminal CUL1 truncation mutant lacking its ROC binding site behaves as a 
dominant-negative mutant whose overexpression caused accumulation of a known Cul1 
substrate, Beta-catenin (Voigt and Papalopulu, 2006). 
 
  The observation that both Cul4 and Ddb1 mutants develop melanotic tumors (Fig. 
2.3) suggests that a CUL4DDB1 ligase may regulate a pathway(s) controlling hemocyte 
development.  A CUL4-dependent ligase has in fact been shown to regulate mammalian 
hematopoeisis; silencing of CUL4A was found to inhibit granulocyte differentiation, 
primarily due to stabilization of the HOXA9 homeodomain protein (Zhang et al., 2003b).  
The dysregulation of the hop-scotch (JAK/STAT) pathway (Harrison et al., 1995; Muller et 
al., 2005), the Toll/ Rel/ Cactus (IL-1R/ NF-kappaB/ IkappaB) pathway, the ribosomal S6 
protein (Dearolf, 1998) have also been implicated in inducing over-proliferation of 
hemocytes and resulting melanotic tumor formation, and therefore may represent other 
possible CUL4DDB1 targets.  Similarly, given that both cul4 and ddb1/ piccolo mutants were 
also found to affect growth control during development (Figs. 2.3, 2.4), other possible classes 
of CUL4DDB1 substrates may include negative regulators of the PI3K-dTOR growth signaling 
pathway. 
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Materials and Methods 
 
Fly stocks and P-element excision-mediated mutagenesis.  Stocks carrying Cul4 mutant 
alleles EP2518 and KG02900 (stocks 17253 and 13335), and Ddb1/ piccolo mutant alleles 
EY01408, pic2, and picdrv3 (stocks 15350, 4278, 1979) were obtained from the Bloomington 
Stock Center (Bloomington, Indiana). The picSO26316 line was from the Szeged Stock Center 
(stock 444, Szeged, Hungary).  The EP2518 P-element in the 3’ UTR of Cul4 was mobilized 
by crossing to w-; Sp/CyO; Dr, Δ 2-3/TM6 flies.  Resulting mosaic males were crossed to 
Pin/Cyo flies, and white-eyed flies representing EP2518 excision events were screened for 
novel Cul4 mutant alleles by crossing with the Cul4KG02900 line.  The breakpoints of Cul46AP, 
Cul411L, and Cul411R were confirmed by sequencing.  The EY01408 P-element in the 5’ UTR 
of Ddb1 was similarly mobilized, and resulting white-eyed flies were tested for 
complementation with the Ddb1S026316 allele.  
 
Mitotic recombination and clonal analysis.  Mitotic recombination was carried out using the 
FLP/FRT technique(Xu and Rubin, 1993).  To generate clones, hs-FLP; FRT42B Ubi-GFP/ 
FRT42B Cul411L, or hs-FLP; FRT82B Ubi-GFP/ FRT82B Ddb1EY01408, or hs-FLP; FRT42D 
Ubi-GFP/ FRT42D Cul1EX, or FRT19A GAL80/ FRT19A Roc1aG1; hsFLP, UAS-GFP; Act-
GAL4 (MARCM method) larvae were heat-shocked for one hour at 37 °C, 48-80 hours after 
egg deposition, and dissected as third instar larvae.  For BrdU incorporation, dissected larvae 
were incubated with 10 uM BrdU in Schneider’s media for 1 hour prior to fixation.   
 
Immunochemistry procedures.  For Western blot analyses, larvae and cells were lysed in 
RIPA (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 0.1% SDS, 0.1% Triton X-
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100, 0.5% sodium deoxycholate), supplemented with 1 mM DTT, 1 mM PMSF, 1 m M 
sodium vanadate, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 10 µg/ml trypsin inhibitor, and 
150 µg/ml benzamidine, and cleared by high speed centrifugation.  Larval lysate were further 
clarified through 0.65 micrometer centrifugal low binding durapore membrane filters 
(Ultrafree-MC, Millipore). Lysates were resolved by SDS-PAGE and analyzed by Western 
blot.  For immunofluorescence analyses, dissected larval tissues were fixed in 4% 
formaldehyde/ PBS-T, blocked in 5% NGS, and immunostained using standard procedures.  
Stained tissues were analyzed using a Zeiss confocal microscope. 
 
Antibody specific for the N-terminus of Drosophila CUL4 was generated in rabbits, 
using a synthetically generated peptide (MSAAKKYKPMDTTELHEN) coupled to KLH 
(Pocono Farms), and affinity purified.  A C-terminal anti-CUL4 antibody was a gift from Dr. 
Hui Zhang (Yale, CT).   Anti-DDB1 was generated in mice using a GST fusion protein 
containing 2/3 of the N-terminal portion of human DDB1 (Zymed).  Rabbit anti-CUL4B was 
generated in rabbits using the synthetic N-terminal peptide 
(MMSQSSGSGDGNDDEATTSK), coupled to KLH (Pocono Farms).  Guinea pig anti-DUP 
was kindly provided by Dr. Terry Orr-Weaver (MIT, MA), and mouse anti-dCyclin A was 
from the Developmental Studies Hybridoma Bank (University of Iowa).  Rabbit anti-Cul1 
(ZL18, Zymed) was used to detect Drosophila CUL1.  Antibodies recognizing human CUL1, 
CUL4, and CDT1 were generated in rabbits (Pocono Farms) and previously described (Hu et 
al., 2004; Michel and Xiong, 1998).  Mouse anti-HA (12CA5, NeoMarkers), mouse anti-
tubulin (NeoMarkers, and goat anti-Skp2 (N-19, Santa Cruz) were obtained commercially. 
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Cell culture, transfection, and RNAi.  HeLa cells were cultured in 5%CO2 in Dulbecco’s 
Modified Eagle’s Medium (Gibco) supplemented with 10% fetal bovine serum (Sigma), 
penicillin, and streptomycin (Invitrogen), and transfected with siRNAs using Oligofectamine 
(Invitrogen).  S2 cells were cultured in Schneider’s/ 10% FBS at 25 °C, and were transfected 
using Lipofectamine (Invitrogen).  RNAi in S2 cells was performed using dsRNA, as 
previously described (Clemens et al., 2000). 
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Figure Legends 
 
Figure 2.1.  Drosophila CUL4 mutants are early larval lethal and partially accumulate the 
replication licensing factor DUP.  (A) The Drosophila CUL4 locus is located on chromosome 
2R at 44B1 and contains 12 exons (filled boxes).  Coding and untranslated region (UTR) are 
represented by black and grey boxes, respectively.  The P-elements KG02900 and EP2518 
are located in the 5’ UTR and 3’ UTR, respectively, of the CUL4 locus.  Three additional 
CUL4 mutant alleles, 11R, 6AP and 11L, were isolated by imprecise repair after mobilizing 
the EP2518 P-element, and are marked at their respective breakpoints within CUL4.  (B) 
Wild type CUL4 protein domains, and truncations resulting from the 6AP, 11R, and 11L 
excision mutants.  Substrate receptor modules (i.e. DDB1) associate with a well-conserved 
domain within the amino-terminus of CUL4, marked in blue.  The C-terminus contains the 
ROC1a binding domain (red), another highly conserved region at the extreme C-terminus 
(orange) of unknown function, and the lysine residue (K767) utilized for conjugation with the 
ubiquitin-like modifier, NEDD8.  Mutants 6AP and 11R are stably expressed C-terminal 
truncation mutants, lacking 65 and 82 amino acids, respectively, and therefore lack the 
neddylation site and the C-terminal domain, but retain the ROC binding domain.  Additional 
P element sequence located at the mutants’ C-termini is colored green; mutants 11R and 6AP 
contain 3 and 4 additional nonsense C-terminal residues, respectively, while 11L contains 54 
additional residues.  The 11L mutant lacks 18 amino acids at the CUL4 C-terminus, thus 
retaining the NEDD8 conjugation site.  (C) CUL4 mutants partially accumulate DUP in the 
absence of DNA damage.  Homozygous mutant 6AP, 11L, 11R, or transheterozygous 
KG/Df(2R) (KG02900 / Df(2R)CA53) or 11L/ Df2R 1st instar larvae were collected, 
homogenized, and analyzed by Western blot.  Mutants 6AP and 11R express truncation 
mutants of the predicted molecular weight (red arrows), while the 11L mutant does not 
express detectable levels of CUL4, and appears null.  KG02900 mutants express 
hypomorphic levels of CUL4.  The green arrow indicates a non-specific band.  DUP levels 
correlate with functional CUL4 levels: The CUL4 hypomorphic mutant KG02900 has 
elevated DUP levels, while mutants 11R, 6AP, and 11L contain higher DUP levels, relative 
to that observed wild type 1st instar larvae. 
 
Figure 2.2.  DDB1/ piccolo is required for viability, and participates in controlling DUP 
levels.  (A) CUL4 and HA-DDB1 co-immunoprecipitate.  HA-DDB1 was ectopically 
expressed in S2 cells, and HA-DDB1 was immunoprecipitated, analyzed by SDS-PAGE and 
Western using anti-CUL4 and anti-HA antibodies.  (B) Endogenous CUL4, DDB1, and DUP 
co-immunoprecipitate.  Anti-CUL4 antibodies specific for the amino-terminus (C4-N) or 
carboxy-terminus (C4-C) were used to immunoprecipitate endogenous CUL4 complexes.  
Western blotting using anti-DUP and anti-DDB1 antibodies revealed the binding of DUP and 
DDB1 with CUL4.  (C) The Drosophila DDB1/ piccolo locus is located on 3R at 87D10 and 
contains 7 exons (labeled as in Figure 1).  Two DDB1 P-element stocks were obtained, 
containing EY01408 or SO26316, both of which are located in the 5’ UTR and are lethal 
when homozygous.  The transversion event within the pic2 allele (G→A), which causes a 
G21D point mutation at the amino acid level, is located at the 5’end of exon 2, as indicated.  
(D) DDB1 mutants partially accumulate DUP in the absence of DNA damage.  Homozygous 
SO26316, EY01408, or transheterozygous pic2/ Df[3R] or picDrv3/ Df[3R]  mutants were 
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collected as second instar larvae, homogenized, analyzed by SDS-PAGE and Western, 
probing for DUP, DDB1, and tubulin. 
 
Figure 2.3.  CUL4 and DDB1 mutants share overlapping phenotypes, including growth 
defects and melanotic tumor formation.  (A) Wild type fly.  (B-D) The piccolo phenotype 
affects bristle and wing development.  DDB1ΔEY01408/pic2 mutants survive until adulthood, 
and most exhibit thin/ missing bristles ((C) is an enlarged image from (B)) and abnormal 
wings (D).  Melanotic tumor formation is prevalent in piccolo/DDB1 mutants (B and D).  (E, 
F) CUL4 -/- (KG02900 mutants shown here), growth arrest early, but survive at a retarded 
size for > 1 week; shown here is the size difference between homozygous and heterozygous 
mutants observed at day 5.  GFP balancer chromosomes (F) were used to distinguish 
heterozygous (GFP +/-) from homozygous (GFP-/-) mutants.  (G) DDB1 -/- larvae (EY01408 
mutants shown here) also growth arrest early (2nd instar), but continue to survive for > 1 
week.  (H-J) Both DDB1 (I, J) and CUL4 (H) mutants develop melanotic tumors during 
larval development.  H.  CUL411L/11L mutants, shown here at early to late 1st instar.  (I, J) 
Roughly 20% of DDB1 mutants develop extensive melanotic tumors, while the majority 
typically develop smaller masses (J).  
 
Figure 2.4.  DDB1 mutants partially recapitulate CUL4 mutant phenotypes.  (A, B) Wild type  
mitotic clones within eye (A) or wing (B) imaginal discs from third instar larvae.  The 
GFP+/+ clones and GFP-/- clones within a single twin spot are roughly equal in size.  BrdU 
immunolabeling marks S phase cells (blue) and exhibits a distinct, non-overlapping pattern 
from DUP immunostaining (red), which is most abundant in early G1 phase cells.  (C, D) 
DDB1EY01408 mutant clones (GFP-/-) in either eye (C) or wing (D) imaginal discs are small in 
size and proliferate poorly, incorporating reduced levels of BrdU relative to phenotypically 
WT surrounding cells.  (E, F) CUL411L mutant clones fail to proliferate when mitotic 
recombination is induced by heat shock at 1st larval instar (F), but are detectable when heat-
shocked at 2nd larval instar.  (E) Like DDB1 mutants, CUL4 mutant clones incorporate BrdU 
poorly, and contain normal levels of DUP.  (F, G) Eye discs dissected from pic2/ Df[3R] (G) 
versus wild type (F) 3rd instar larvae are reduced in size, and have reduced/ irregular BrdU 
incorporation.  (I, J, K) CUL4 and DDB1 homozygous mutants exhibit reduced proliferation.  
First instar brain lobes dissected from DDB1EY01408 (K) or CUL411L (J) mutants, compared to 
wild type (I), show reduced BrdU incorporation.  (L) DDB1EY01408 clones are 75% smaller in 
size than wild type clones.  The size of GFP+/+ versus GFP-/- clones from wild type or 
DDB1 twin spots were measured in area, in arbitrary units (pixels).  (M) CUL4 has a longer 
half-life than DDB1.  S2 cells were treated with cycloheximide (CHX, 40 ug/mL), and 
collected over an 8 hour timecourse.  Lysates were resolved by SDS-PAGE, and analyzed by 
Western to detect the half-lives of CUL4, DDB1, and cyclin A. 
 
Figure 2.5.  The degradation of CDT1/ DUP may be redundantly controlled by CUL4-DDB1 
and CUL1-dependent E3 ubiquitin ligases during S phase.  (A) CUL1EX clones degrade DUP 
normally.  Immunolabeling of CUL1EX clones (GFP-/-) for BrdU incorporation and DUP 
levels revealed distinct, non-overlapping distributions of S phase and DUP positive cells.  (B, 
C) Dysregulated DUP levels are observed in few ROC1a mutant clones.  ROC1aG1 clones 
were positively marked (GFP +/+), and immunostained as in (A).  Some ROC1a mutant 
clones have elevated cytoplasmic DUP levels (B), and others that are BrdU positive also 
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inappropriately contain DUP (C).  (D) DUP, CUL1, and CUL4 co-immunoprecipitate.  
Immunoprecipitations using anti -DUP, -CUL1, -CUL4, and –myc (control) and S2 cell 
lysates were resolved by SDS-PAGE, and probed by Western blot as indicated.   (E) 
CUL4DDB1 control DUP levels in S2 cells, in the presence or absence of DNA damage.  
CUL4DDB1 was silenced in S2 cells by treatment with CUL4 or DDB1 dsRNA for 4 days, and 
subjected to ionizing radiation (110 Gy), or left untreated.   (F) Disabling both CUL1-SKP2 
and CUL4-DDB1 E3 ligases by RNAi in HeLa cells more completely protects CDT1 from 
degradation during S phase than disrupting either E3 ligase alone.  HeLa cells were 
transfected with synthetic siRNAs corresponding to the indicated genes, lysed 48 hours later, 
and analyzed by Western blot. 
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CHAPTER III 
 
Alternate substrate adaptors and potential substrates of the CUL4-dependent E3 
ubiquitin ligase 
 
 
 
DDB1-dependent and –independent functions of CUL4 
 
 Our studies of CUL4 and DDB1 in Drosophila (Chapter II) coupled with genetic 
studies in other model organisms, including S. pombe, C. elegans, and mice have established 
that CUL4 and DDB1 are essential for development, and have pleiotropic functions that 
extend beyond the DNA damage response.  These studies have also indicated that DDB1 
serves as a substrate receptor molecule for CUL4, but that it does not account for the full 
scope of CUL4 activity, suggesting an even broader array of complexes assembled and 
potential substrates targeted by the CUL4 E3 ubiquitin ligase (Figure 3.3).  Studies in S. 
pombe have very recently demonstrated a role for CUL4 in heterochromatin formation, by 
assembling with a DDB1-like molecule, Rik1 (unique to S. pombe), and two additional 
adaptor molecules (Raf1/ Dos1/ Clr8 and Raf2/ Dos2/ Clr7) (Horn et al., 2005; Li et al., 2005; 
Thon et al., 2005).   
  
 Structural analyses of DDB1 support the genetic evidence for the existence of 
additional DDB1-like molecules that may associate with CUL4.  Other well-conserved beta-
propeller domain-containing proteins that structurally resemble DDB1, including SAP130 
(Splicing and Polyadenylation factor) and CPSF160 (Cleavage and Polyadenylation 
 63
Specificity Factor) (Li et al., 2006b; Neuwald and Poleksic, 2000) are likely candidate 
substrate receptor molecules for the CUL4 ligase.  Preliminary data in our lab suggests that 
CUL4A can in fact co-immunoprecipitate with SAP130 and CPSF160 when ectopically 
expressed in mammalian cells (personal communication, Y. Xiong, unpublished results).  
Such potential associations are suggestive of possible roles for the CUL4 E3 ligase in 
regulating factors involved in mRNA processing events (Figure 3.3).  Further studies will be 
required to evaluate the functional consequence of such interactions and possible substrates 
that may be targeted. 
 
Roles for CUL4 and DDB1 in proliferation and growth 
 A deeper understanding of the full range of functions of the CUL4DDB1 E3 ligase 
awaits further analysis as well.  Our studies in Drosophila support existing data indicating a 
role for the CUL4DDB1 ligase in regulating CDT1/DUP levels during S phase, and following 
DNA damage (chapter II).  The expression of CUL4 and DDB1 fluctuates slightly during the 
course of development, but with similar patterns that are coincident throughout (Fig 3.2), 
indicating that association between DDB1 and CUL4 would be viable at all developmental 
stages in which CUL4 is expressed.  As disruption of DDB1 appears less severe (and 
presumably would affect fewer cellular processes) than CUL4 disruption in Drosophila, and 
since DDB1 does not appear to have CUL4-independent functions, a more detailed analysis 
of the growth and proliferation defects of DDB1 mutants could point to other potential 
substrates of the CUL4DDB1 ligase. 
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 The growth defect observed in CUL4 and DDB1 mutants (Chapter II) indicate that 
CUL4DDB1 could be involved in controlling a negative regulator of the growth signaling 
pathway.  For example, the potential involvement of CUL4DDB1 in regulating PTEN or TSC1/ 
TSC2, could be suggestive of the oncogenic function of CUL4 observed in breast and other 
cancers.  The growth defect in DDB1 mutants is evident as a piccolo phenotype with clear 
disruption of bristle growth (Chapter II).  Given that the piccolo phenotype is highly visible 
and traceable, rescue experiments using Drosophila DDB1 mutants could be used to test 
candidate growth effectors as CUL4DDB1 substrates.  For example, testing whether reducing 
levels of PTEN, TSC1, or TSC2 in DDB1 mutants can rescue the piccolo phonotype could 
quickly establish whether these growth regulators are controlled by CUL4DDB1.  In addition, a 
scaled-up screen could be conducted to identify other genes that may be able to rescue the 
piccolo phenotype, which could potentially lead to the identification not only of possible 
CUL4DDB1 substrates, but could perhaps also identify novel growth regulators. 
 
CUL4-interacting proteins 
 In attempting to identify other potential CUL4-interacting proteins, we have also 
employed biochemical assays, such as immunoprecipitation and mass spectrometric analyses. 
Using our anti-CUL4-N antibody and S2 cell lysates, CUL4 immunocomplexes were purified 
and analyzed by mass spectrometry (Figure 3.1).  Immunoprecipitations (IPs) of CUL4 were 
incubated in the absence or presence of CUL4-N competing peptide (a 15 amino acid peptide 
corresponding to the epitope used for anti-CUL4-N production), to ascertain specific 
interactions with the anti-CUL4-N antibody.  Bands that were present in the minus-peptide IP, 
but which were competed away in the plus-peptide IP, were submitted for mass spectrometric 
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analysis.  Two prominent bands were positively identified as CUL4, likely representing 
neddylated and unneddylated forms.  Although previously identified CUL4-interacting 
proteins, such as CAND1, signalosome subunits, DDB1, or ROC proteins, were not 
identified in this experiment, and some identified bands such as the heat shock protein 
(AE003708 NID) are notoriously “sticky” proteins that probably represented non-specific 
interactions, other bands identified could be relevant to CUL4 function.  Interestingly, the 
ribosomal protein (L6) was found to co-immunoprecipitated with CUL4, which could be 
indicative of a growth-related regulatory function of CUL4. Other proteins, including 
CG30069 (uncharacterized protein with putative cell cycle function) and CG10102 (RNA-
directed DNA polymerase) are newly identified interactions and could be involved in CUL4-
mediated regulation of proliferation.  Another interesting interaction with the large subunit of 
RNA polymerase II was also identified (Fig. 3.1), as was an interaction with the small 
subunit of RNA polymerase II, in a separate IP-Mass spec experiment using wild type 
Drosophila embryos (data not shown).  RNA polymerase II has previously been identified in 
association with CUL4, DDB1, and CSA, as part of a complex involved in transcription-
coupled repair of damaged DNA (Groisman et al., 2003).  Further exploration of the 
functional consequence of the interaction between CUL4 and RNA Polymerase II in the 
presence or absence of DNA damage will lead to a greater understanding of CUL4DDB1 
function.   
 
CUL4 promotes both mono- and poly-ubiquitination of substrates 
 Recent studies in mammalian cells have indicated another unique property of CUL4 
amongst the cullin family; CUL4 is not only able to promote the polyubiquitination and 
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subsequent degradation of target substrates, but may also serve to monoubiquitinate select 
substrates to regulate their function.  For example, monoubiquitination of histone H2A and 
XPC (the xeroderma pigmentosum group-C protein involved in damaged DNA recognition) 
by a CUL4DDB1-DDB2 complex in response to DNA damage appears to promote the ability of 
these molecules to contribute to repair of damaged DNA, and does not lead to their 
destruction by the proteasome (Kapetanaki et al., 2006; Sugasawa et al., 2005).  Therefore, 
newly identified CUL4-interacting proteins/ substrates may not necessarily be subjected to 
targeted polyubiquitination and degradation, but may be activated, inactivated, re-localized, 
or otherwise functionally altered by CUL4-mediated monoubiquitination. 
 
CUL4 utilizes additional substrate receptors through association with DDB1 family proteins 
 CUL4 often appears to require more than DDB1 or other DDB1-like proteins in 
recruiting substrates for ubiquitination (Figure 3.3).  Several WD-40 domain-containing 
proteins have been identified in CUL4 complexes in association with DDB1, including 
DDB2, CSA, DET1, Cdt1, and Clr8 (through Rik1 in S. pombe), and appear to be required 
for ubiquitination of target substrates.  It is conceivable and likely that these WD-40-
containing proteins belong to a larger, yet undefined family of proteins, analogous to the F-
box family of proteins interacting with SKP1 of the CUL1 complex, that preferentially 
associate with DDB1 or DDB1-like proteins to specify substrate recruitment.  Several of 
these identified mammalian WD-40 proteins share close homologues in Drosophila, and can 
potentially be tested genetically for interactions with CUL4 and DDB1, SAP130, or 
CPSF160.  One of these proteins, Cdt2 (in S. pombe), has a close homologue, denticleless, in 
Drosophila.  denticleless is required for development and proper denticle formation during 
 67
embryogenesis, and is an E2F-responsive gene (Cathy Silver Key, personal communication), 
and would therefore be interesting to evaluate whether it could be partly involved in CUL4-
mediated control of proliferation.  Since CUL4 functions are highly pleiotropic, the full 
scope of such functions may be masked in CUL4 mutants in vivo.  Therefore, an in vivo 
study of other proteins that mediate substrate specificity of the CUL4 complex, and therefore 
regulate a smaller subset of CUL4 function, will undoubtedly lead to a greater understanding 
of CUL4 function. 
 
Targeting of CUL4 in viral infection and tumorigenesis 
 The cellular proteins targeted by viruses during viral infection often also represent 
proteins targeted in tumorigenesis (O'Shea, 2005).  CUL4 is known to be hijacked by two 
different mechanisms during viral infection by hepadnaviruses or paramyxovirus. 
Hepadnaviruses encode the C protein, which associates with DDB1 to control viral genome 
replication.  The CUL4DDB1 complex is co-opted by the V proteins of paramyxoviruses 
(mumps virus), thereby polyubiquitinating STAT1 and STAT3 and marking them for 
degradation (Ulane and Horvath, 2002; Ulane et al., 2003).   Interestingly, the development 
of melanotic tumors in CUL4 and DDB1 mutants (chapter II), which can result from 
dysregulated JAK/STAT signaling, suggests that CUL4DDB1 may utilize other cellular 
adaptors to ubiquitinate STATs in vivo.  Further studies aimed at determining the 
physiological substrate(s) responsible for melanotic tumor formation in CUL4 or DDB1 
Drosophila mutants, could be another means of fully appreciating CUL4DDB1 function in vivo, 
and in the context of its over-expression in breast and other cancers.   
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 Genomic amplification and overexpression of human CUL4A in breast cancer 
suggests a potential function of CUL4 in promoting cell survival.  Generation of transgenic 
flies over-expressing CUL4 could provide an opportunity to test this possibility at the 
organismal or cellular level, as flies have been utilized as a model system of tumorigenesis 
(Higa et al., 2003; Hu et al., 2004).  Using the UAS/ GAL4 system of expression, CUL4 can 
be preferentially over-expressed in the whole organism, in a tissue-specific manner, or in 
clones of cells via the FLP/FRT system (Xu and Rubin, 1993), and examined to determine 
whether normal proliferation and/or differentiation of affected tissue is perturbed. 
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Figure 3.1.  Mass spectrometric 
analysis of CUL4 complexes, 
purified from S2 cells.  CUL4 
immunocomplexes were purified 
from Drosophila S2 cell lysates in 
the presence or absence of CUL4 
competing peptide, and were 
resolved by SDS-PAGE.  Bands 
were visualized using Coomassie 
blue.  Marked bands indicate those 
that bound to CUL4 specifically, as 
i n d i c a t e d  b y  t h e i r  r ed u c ed 
association with CUL4 in the 
presence of competing peptide.  
Noted bands were excised and 
identified by mass spectrometric 
analysis: B7: CG30069, cell cycle/ 
unknown function; B10: DNA-
d i r ec t ed  RNA Po l I I ;  B11: 
neddylated dCul4; B12: dCul4; C2:  
heat shock protein; C3: Fructose 1,6 
bisphosphate; C4: Fibrillarin; C5: 
R i b oso m a l  P ro t e in  L6 ;  C6: 
ADP/ATP translocase; C7: RNA-
directed DNA polymerase.      x
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Figure 3.2. CUL4 and DDB1 transcripts exhibit similar expression patterns during 
Drosophila development. RT-PCR of CUL4 and DDB1 first strand cDNAs generated from 
Drosophila mRNA isolated throughout development (Rapid-Scan Gene Expression Panel; 
OriGene Technologies) .
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Figure 3.3. Complexes assembled by CUL4 E3 ligases. (A) Hijack of the CUL4DDB1 ligase by the 
mumps V protein targets STAT1 or STAT3 for ubiquitination.  (B) In S. pombe, CUL4 associates with 
DDB1 and CDT2 to target the ribonucleotide reductase inhibitor, Spd1, for ubiquitination.  (C) A 
complex containing CUL4, DDB1, DET1, and COP1 has been described to ubiquitinate c-jun.  (D) In 
S. pombe, CUL4 also assembles with RIK1, a DDB1-like protein, along with additional adaptor 
proteins Clr7 and Clr8, to promote heterochromatin formation, though the relevant substrate(s) is 
unknown.  (E, F) In mammalian cells subjected to UV, CUL4DDB1 interacts directly with the substrate 
CDT1, leading to its degradation, and preventing S phase entry (E).  (F) Upon DNA damage, DDB2 
appears to be important for localizing the CUL4DDB1 complex to sites of DNA damage, allowing the 
monoubiquitination of histone H2A and XPC (a damaged DNA binding protein), and repair of DNA.
(G, H) CUL4 may also associate with two other proteins that share homology with DDB1: SAP130 
(G), and CPSF160 (H), implicating CUL4 in processes affecting splicing and mRNA processing.
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Summary 
 
The metazoan cell cycle is driven by the timely and composite activities of cyclin-
dependent kinases (CDKs). Among these, cyclin D-dependent kinases phosphorylate the pRb 
family proteins early in the G1 phase of the cell cycle and thereby advance cells beyond the 
restriction point.  Increasing evidence suggests that cyclin D-dependent kinases might affect 
events other than Rb pathway-mediated entry into S phase, such as accumulation of cell mass.  
However, little is known about cyclin D activity toward Rb-independent pathway(s) or non-
pRb substrates. We designed a yeast three-hybrid screen to identify potential regulators and 
substrates of cyclin D1-CDK6 and isolated TSC2 as a cyclin D1 binding protein. In cultured 
cells, co-expression of cyclin D1-CDK6 leads to increased phosphorylation and decreased 
detectable levels of both TSC1 and TSC2 proteins, and promotes the phosphorylation of the 
mTOR substrates 4E-BP1 and S6K1, two key activators of cell growth that are negatively 
regulated by the TSC1-TSC2 complex.  At the cellular level, ectopic expression of cyclin D1 
restored the cell size decrease caused by TSC1-TSC2 expression.  Intriguingly, down 
regulation of TSC proteins was also observed by the expression of a mutant cyclin D1 that is 
unable to bind to CDK4/6, or by the co-expression of cyclin D1 with either an INK4 inhibitor 
or with catalytically inactive CDK6, indicating that cyclin D may regulate TSC1-TSC2 
independent of CDK4/6.   Together, these observations suggest that mammalian D-type 
cyclins participate in cell growth control through negative regulation of TSC1-TSC2 function. 
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Introduction 
Studies in S. cerevisiae that laid the groundwork for our understanding of the cell 
division cycle also established its critical link to cell growth control—regulating the 
accumulation of cellular mass (Hartwell and Unger, 1977; Nurse, 1975). Cell cycle control 
and cell growth control must be coordinately regulated to maintain homeostatic cell size, yet 
the two processes are separable (Jorgensen and Tyers, 2004). The use of temperature 
sensitive cell division cycle mutants demonstrated that yeast cells blocked from progressing 
through the cell cycle could still continue to increase in size. However, when cell growth was 
blocked by nutrient deprivation or by inactivating key biosynthetic genes, the cell cycle could 
no longer proceed (Hartwell and Unger, 1977). Although disruptions in the control of the cell 
cycle, and more recently of cell growth, have been widely recognized as major contributors 
to tumorigenesis (Deshpande et al., 2005; Shamji et al., 2003), the molecular mechanisms 
linking the two processes are not well understood. 
 
Entry into the proliferative cell cycle and progression through G1 is initiated by 
extracellular mitogenic signaling, which in mammalian cells leads to the synthesis of D-type 
cyclins.  Two catalytic subunits, CDK4 and CDK 6 (CDK4/6), can interact with any of three 
D-type cyclins (D1, D2, and D3) to form up to six distinct kinase holoenzymes (collectively 
referred to as cyclin Ds-CDK4/6).  Although individual D-type cyclins, and to lesser extent 
CDK4 and CDK6, are expressed differentially in a tissue-specific manner, different cyclin 
Ds-CDK4/6 complexes are biochemically similar if not indistinguishable.  CDK4/6 are 
negatively regulated by two families of CDK inhibitors, the INK4 (inhibitors of CDK4) 
family, which can bind CDK4/6 and prevent their association with D-type cyclins, and the 
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CIP/KIP family, which can bind to and inhibit cyclin Ds-CDK4/6 in a ternary complex (Pei 
and Xiong, 2005).  Active cyclin Ds-CDK4/6 phosphorylate pRb and two other pocket 
proteins p107 and p130, thereby lifting repression of the E2F transcription factors and 
permitting expression of genes necessary for DNA replication during S phase. 
 
However, some aspects of cyclin D and CDK4/6 biology cannot be reconciled by 
their kinase activity toward pRb alone. For example, as some cells undergo senescence and 
permanently withdraw from the cell cycle, such as during myotube differentiation, the level 
of cyclin D in the cell actually accumulates rather than decreases (Franklin and Xiong, 1996). 
Furthermore, a cyclin D1 mutant ineffective at targeting pRb retains transforming ability in 
cooperation with Ras (Zwicker et al., 1999). In a similar vein, disruption of cyclin D-CDK4/6 
function by p16INK4a over-expression in melanocytes exhibited phenotypically distinct 
consequences from pRb inactivation (Yu et al., 2003).  Cyclin D1 and CDK4 are dispensable 
for proliferation in flies and mice, but do appear to play a role in growth control, as 
disruption of either cyclin D or CDK4 results in reduced cell and overall organism size 
(Datar et al., 2000; Kozar et al., 2004; Meyer et al., 2000)). In fact, over-expression of cyclin 
D and CDK4 in flies leads to an increase in cell and organ size in an pRb-independent 
manner (Datar et al., 2000; Xin et al., 2002). Genetic studies have suggested a role for cyclin 
D-CDK in cell growth control by acting upstream of Hif-1 prolyl hydroxylase (Hph) and the 
mitochondrial ribosomal protein mRpL12 (Frei and Edgar, 2004; Frei et al., 2005). 
 
Despite the broad effects of cyclin D-CDK on cell cycle and cell growth control, little 
is known about its substrates other than the pRb family. Recently, Smad3 was identified as a 
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direct cyclin Ds-CDK4/6 substrate, linking cyclin D-CDK activity with another effector of 
proliferative control (Matsuura et al., 2004). In addition, CDK-independent activation of 
several transcription factors by cyclin D have been described (Fu et al., 2004).  The 
identification of other cyclin D-CDK4/6 targets could lead to a greater understanding of its 
role in cell cycle progression, cell growth control, and tumorigenesis. The limited number of 
identified cyclin Ds-CDK4/6 substrates could be partly due to the technical difficulties 
associated with identifying the transient association of a kinase and substrate.  In this study, 
we describe a protein yeast three-hybrid system capable of assembling a cyclin-CDK 
complex designed to identify potential binding proteins. We isolated the cell growth 
regulator TSC2 using this system, and further characterization of this interaction suggests 
that the TSC1-TSC2 complex may be a novel target of cyclin D-CDK4/6 activity involved in 
cell growth control. 
 
Results 
Design of a protein yeast three-hybrid system 
The conventional two-hybrid system is capable of detecting only binary protein-
protein interactions. We reasoned that because some protein interactions with CDKs may be 
cyclin-dependent, the use of a cyclin-CDK complex as “bait” may allow the identification of 
novel cyclin-CDK-interacting proteins. In order to investigate this possibility, we designed a 
modified version of the yeast two-hybrid system that allows the formation of a ternary 
protein complex in yeast.  Similar systems have been described previously (Gordon and 
Buchwald, 2003; Licitra and Liu, 1996; Pause et al., 1999; Sandrock and Egly, 2001; Tirode 
et al., 1997). To facilitate interactions of potential CDK substrates, we used a CDK6 point 
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mutant (CDK6K43M) that is incapable of binding to ATP and therefore could form a more 
stable complex with the substrate. A similar mutant has previously been shown to stabilize 
the interaction of cyclin D-CDK4 with pRb (Kato et al., 1993). We fused CDK6K43M to the 
GAL4 DNA binding domain (GAL4BD) and cyclin D1 to the GAL4 nuclear localization 
signal (NLS).  Expression of GAL4BD-CDK6K43M and NLS-cyclin D1 proteins was driven 
by distinct promoters within a single plasmid carrying the TRP marker. The prey cDNA was 
fused to the GAL4 activation domain (GAL4AD) and expressed from a conventional two-
hybrid plasmid expressing the LEU marker. Interaction of bait and prey results in the 
reconstitution of the GAL4 transcriptional activator and drives expression of the HIS3 gene, 
allowing growth on media lacking histidine. This system is capable of detecting binary 
interactions between CDK6K43M and the prey as well as ternary interactions involving 
CDK6K43M, cyclin D1, and the prey. 
 
 In order to confirm the efficacy of the three-hybrid system, we tested for binding of 
proteins known to interact with CDK6 in a cyclin D-dependent manner. We assessed the 
ability of the CDK6 substrates pRb or p130 to interact with CDK6K43M either alone or in the 
presence of cyclin D1 or cyclin D3. As expected, pRb and p130 were able to interact with 
CDK6K43M in the presence of cyclin D1 or D3, but failed to interact with CDK6 K43M alone 
(Figs. 4.1a, b). The CDK4/6 inhibitors, p15INK4b and p18INK4c, are known to interact with 
CDK4/6 independently of cyclin D (Guan et al., 1994). Both p15INK4b and p18INK4c showed 
positive interaction with CDK6K43M, either in the presence or absence of cyclin D1 or D3 
(Figs. 4.1a, b). These interactions were confirmed by β-galactosidase activity in yeast co-
transformed with CDK6 K43M-cyclin D1 and either p21, pRb, or p15INK4b (data not shown). 
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Detection of CDK6/cyclin D interacting proteins using a yeast three-hybrid library screen 
After confirming the feasibility of the three-hybrid system, we sought to identify 
proteins that could interact with the CDK6K43M-cyclin D1 complex by screening a human 
cDNA library generated from the HaCaT keratinocyte cells. Of an estimated 106 colonies 
screened, 512 were isolated on histidine-minus growth medium.  Of 135 colonies further 
analyzed, 96 were positive for β-galactosidase staining.  A more stringent assay revealed that 
71 of the β-galactosidase positive colonies were able to sustain growth in the presence of 30 
mM 3-amino-triazole (3-AT), a HIS3 inhibitor.  Sequence analysis of these clones indicated 
that the majority represented known CDK6-cyclinD1 interacting proteins, including 31 
isolates encoding D-type cyclins, 14 isolates representing members of the INK4 family of 
CDK inhibitors, 9 isolates representing the CDK inhibitor p21, and 3 isolates representing 
p130, a pRb family member. Of the genes encoding proteins previously unrecognized as 
interacting with CDK6-cyclin D1, a truncated form of TSC2 was isolated 20 times and 
formed a stable interaction with the CDK6K43M-cyclin D1 complex, as judged by strong β-
galactosidase activity and growth in the presence of 30 mM 3-AT. The prey plasmid 
encoding the carboxyl-terminus of human TSC2 (TSC2-C) was found to initiate at amino 
acid 1297, yielding a protein of 511 amino acids with a calculated molecular weight of 56 
kDa. When re-transformed into yeast, the interaction of TSC2-C with CDK6K43M was 
dependent on the presence of either cyclin D1 or D3 and was also capable of interacting with 
both cyclins in a binary fashion (Fig. 4.1b). An interaction between p18INK4c and CDK6K43M 
confirms expression of the kinase (Fig. 4.1b). A similar two-hybrid screen of the HaCaT 
cDNA library using GAL4BD-CDK6K43M as bait alone revealed that of 39 isolated colonies, 
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neither p21, p130 nor TSC2 were represented (data not shown), consistent with the notion 
that these proteins interact preferentially, if not only, with cyclin D-CDK complexes.  
 
TSC2 interacts with the D-type cyclins 
To confirm the interaction of TSC2 with cyclin D proteins in mammalian cells, 293T 
cells were transiently transfected with Flag-tagged full length TSC2 in combination with one 
of the three D-type cyclins. Anti-Flag immunoprecipitates were resolved by SDS-PAGE and 
each of the three D-type cyclins were present in the Flag-TSC2 immunocomplexes (Fig. 
4.2a). The cyclin box of cyclin D1, the region that is sufficient for association with CDK4/6, 
does not bind to TSC2 (Fig. 4.2b). Rather, the amino and carboxyl termini of cyclin D1 retain 
ability to associate with TSC2, consistent with the formation of a ternary complex between 
TSC2-cyclin D1-CDK6 observed in the yeast three-hybrid assay. 
 
The TSC1-TSC2 complex acts to negatively regulate cell growth by inhibiting the 
protein kinase mTOR (Gao et al., 2002; Inoki et al., 2002; Tee et al., 2002).  The TSC 
complex is sensitive to growth conditions—in the presence of growth factors and mitogens 
TSC2 is multiphosphorylated, rendering TSC1-TSC2 inactive, and in their absence TSC2 is 
hypophosphorylated, allowing TSC1-TSC2 to actively represses mTOR (Han et al., 2004; 
Inoki et al., 2002; Li et al., 2003c; Ma et al., 2005; Manning et al., 2002; Potter et al., 2002; 
Roux et al., 2004; Tee et al., 2002). To determine whether growth conditions might impact 
the association of cyclin D1 with TSC2, we performed co-immunoprecipitation experiments 
from serum starved cells with or without serum stimulation (Fig. 4.2c). Consistent with 
previous observations, we observed more stable detection of TSC2 when its plasmid was co-
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expressed with one encoding TSC1 (Benvenuto et al., 2000). Though TSC2 was detectable in 
the anti-cyclin D1 immunocomplex from serum starved cells, its association increased as the 
cells were stimulated with 10% serum (Fig. 4.2c, lanes 13-18). Together these data 
demonstrate an association between cyclin D1 and TSC2 that allows for CDK4/6 binding and 
is subject to regulation by serum-derived growth signals. 
 
Cyclin D1 overexpression abrogates the growth inhibitory effects of TSC1-TSC2 
In the absence of functional TSC1-TSC2, metazoan cells are quantitatively larger and 
conversely, excess TSC1-TSC2 causes a measurable decrease in overall cell size (Gao and 
Pan, 2001; Potter et al., 2002; Rosner et al., 2003; Tapon et al., 2001). A physical interaction 
of cyclin D1-CDK with the TSC1-TSC2 complex implies a role for cyclin D1-CDK in cell 
growth control, consistent with previous conclusions based on Drosophila genetics (Tapon et 
al., 2001). We therefore evaluated the effect of cyclin D1 expression on TSC1-TSC2 function 
by using flow cytometry to measure changes in cell size—determined by the forward scatter 
(FSC) of light of transfected cells. As expected, when TSC1 and TSC2 were ectopically 
expressed in U2OS cells, a decrease in mean FSC of G1 phase cells was observed (Fig. 4.3a). 
A similar but less pronounced effect on cell size was evident in G2/M phase cells (data not 
shown). The addition of cyclin D1 to cells over-expressing TSC1-TSC2 nearly restored the 
average cell size to control levels (Fig. 4.3a). TSC1 and TSC2 have also been proposed to 
affect cell cycle progression (Miloloza et al., 2000; Potter et al., 2001; Soucek et al., 1997; 
Tapon et al., 2001). TSC1-TSC2 over-expression caused only subtle alterations in cell cycle 
distribution, leading to a slight increase in the G1 population, which again was abrogated 
when cyclin D1 was co-expressed (Fig. 4.3a). 
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Mammalian cell growth is regulated by the kinase activity of mTOR directed at either 
inhibiting or activating, respectively, two primary targets—4E-BP1 and S6K1 (Fingar et al., 
2002). The activity of mTOR, in turn, is negatively regulated by the TSC1-TSC2 complex 
which itself may be controlled in part by cyclin D-CDK4/6 (Fig. 4.3a). Therefore, to 
determine whether the antagonizing effect of cyclin D1 toward TSC complex is mediated 
through the mTOR activity, we assayed for mTOR-dependent phosphorylation of 4E-BP1 
and S6K1 under conditions of cellular proliferation or quiescence. 293T cells were 
transfected with plasmids encoding either HA-4E-BP1 alone or with cyclin D and CDK4, 
and cultured either with 10% serum or in the complete absence of serum for one hour before 
harvesting. Under normal growth conditions, HA-4E-BP1 can be seen both as a faster 
migrating non-phosphorylated band and as a more slowly migrating phosphorylated band 
(Fig. 4.3b lane 2). Upon serum withdrawal, HA-4E-BP1 collapses to the non-phosphorylated 
form (Fig. 4.3b). However, under the same conditions co-expression of cyclin D1-CDK4 
substantially prevented the loss of phosphorylated HA-4E-BP1. Serum induced 
phosphorylation of 4E-BP1 is dependent on mTOR (Burnett et al., 1998; Gingras et al., 
1998), and the repression of mTOR following serum depletion requires the activity of the 
TSC1-TSC2 complex (Jaeschke et al., 2002; Kwiatkowski et al., 2002). Therefore, these data 
are consistent with the suggestion that cyclin D1-CDK4 acts to protect the mTOR signaling 
pathway from TSC1-TSC2 function. 
 
Similar results were obtained when the activity of S6K1 was examined under 
conditions of serum withdrawal. Plasmid encoding HA-S6K1 was transfected into 293T cells, 
either independently or in conjunction with cyclin D1-CDK4. Twenty-four hours following 
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transfection, serum was removed and the cells were collected 2, 4, or 8 hours later. HA-S6K 
was immunoprecipitated from cell lysates and assayed for its ability to phosphorylate GST-
S6 (Fig. 4.3c).  Under standard growth conditions, HA-S6K efficiently phosphorylated GST-
S6, but as the duration of serum starvation increased, HA-S6K activity diminished (Fig. 4.3c 
lanes 3, 5, 7). However, when plasmids encoding cyclin D1-CDK4 were co-expressed with 
HA-S6K, a partial attenuation of the rapid decline in S6K activity was observed at each time 
point (Fig. 4.3c lanes 4, 6, 8). Furthermore, while overexpression of TSC1 and TSC2 can 
reduce the activating phosphorylation of S6K1 at threonine 389 by mTOR, the co-expression 
of cyclin D1 either alone or in combination with CDK6 restores mTOR-dependent 
phosphorylation of S6K1 (Fig. 4.3d). Thus, high cyclin D-CDK4/6 levels repress the ability 
of the TSC1-TSC2 complex, when boosted by either serum depletion or its overexpression, 
to inhibit mTOR signaling. 
 
TSC1 and TSC2 are phosphorylated in a CDK-dependent manner 
Two lines of evidence suggest that cyclin D-CDK4/6 may promote the 
phosphorylation of TSC1 and/or TSC2: (i) physical interaction of the TSC1-TSC2 complex 
with cyclinD-CDK4/6 (Figs. 4.1 and 4.2), and (ii) a retarded mobility of both TSC1 and 
TSC2 on SDS-PAGE when cyclin D and CDK4/6 were co-expressed (Fig. 4.3d). To examine 
the phosphorylation state of TSC2 in the presence of CDKs in vivo, Saos-2 cells were 
transfected with plasmids encoding HA-tagged TSC2-C and cyclin D1, CDK6, or cyclin D1-
CDK6 and labeled with 32P-orthophosphate.  We observed a marked increase in the 
phosphorylation state of TSC2-C in the presence of both cyclin D1 and CDK6 (Fig. 4.4a) 
relative to either subunit alone.  This observation was also made in vitro using bacterially 
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expressed TSC2-C and extracts from insect Sf9 cells expressing cyclin D1-CDK6 (data not 
shown).  In order to evaluate the potential kinase activity of other CDKs toward TSC2, 
cDNAs for TSC2 and myc-TSC1 were co-transfected into U2OS cells with different cyclin 
and CDK combinations, and total cell lysates were resolved by SDS-PAGE (Fig. 4.4b).  As 
expected, co-expression of cyclin D1 and CDK6 caused a mobility shift of TSC2, while the 
catalytically inactive CDK6K43M mutant failed to alter the mobility of TSC2 (Fig. 4.4b).  Calf 
intestinal phosphatase (CIP) treatment of extracts confirmed that the mobility shift was due 
to phosphorylation (Fig. 4.4c).  Interestingly, the mobility of TSC1 was also retarded by co-
expression with cyclin D1-CDK6, but not by cyclinD1- CDK6K43M. The phosphorylation of 
TSC1 on at least three sites, T417, S584, and T1047, by cyclin B-CDK1 has been described 
(Astrinidis et al., 2003; Ballif et al., 2005). We found that, in fact, several different cyclin-
CDK pairs, including cyclin D-CDK4 (data not shown), cyclinE-CDK2, cyclinA-CDK1, and 
cyclinA-CDK2 promoted the apparent phosphorylation of both TSC1 and TSC2 upon co-
expression (Fig. 4.4b). These results suggest that both TSC1 and TSC2 can be 
phosphorylated in a CDK-dependent manner, either directly or indirectly, and offer one 
potential mechanism for the regulation of the TSC1-TSC2 complex by cyclin-CDK partners. 
 
Down-regulation of TSC1-TSC2 by cyclin D 
Another notable consequence of the concomitant expression of plasmids encoding 
cyclin D-CDK6 (WT or K43M) and the TSC1-TSC2 complex is a decrease of both TSC1 
and TSC2 protein levels (Figs. 4.3d and 4.4b).  Overexpression of cyclin D1 alone is able to 
cause the down-regulation of co-expressed myc-TSC1 and HA-TSC2, although this effect is 
dependent on growth conditions (Fig. 4.2b). HA-TSC2 co-expressed with myc-TSC1 and 
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cyclin D1 is most stable under serum-starved conditions, and becomes increasingly sensitive 
to cyclin D1-mediated down-regulation upon serum re-stimulation (Fig. 4.2b, lanes 4, 8, 12).  
Cyclins D2 and D3 elicit a similar effect on decreasing TSC1-TSC2 under the same assay 
conditions (data not shown).  To determine whether expression of cyclin D1 alone might 
down-regulated TSC protein levels through the activation of endogenous CDK4/6, we 
utilized cyclin D1K112E, which is a cyclin box mutant that fails to bind or activate either 
CDK4 or CDK6 (Inoue and Sherr, 1998; Zwijsen et al., 1997). As shown in Figure 4.5a, 
cyclin D1K112E is also capable of down-regulating myc-TSC1 and HA-TSC2, demonstrating 
the kinase-independence of this activity. 
 
For a further confirmation of a CDK-independent down regulation of ectopic TSC1 
and TSC2 by co-expressed cyclin D1, we took advantage of the differential inhibitory modes 
of the two families of CDK inhibitors, the INK4 vs. the CIP/KIP family. p16INK4a, which 
forms a binary complex with CDK4/6, is unable to protect myc-TSC1 or HA-TSC2 from 
down-regulation by cyclin D1 expression (Fig. 4.5b).  In contrast, p21CIP, which forms a 
ternary complex with cyclin D-CDK4/6, is able to attenuate the down-regulation of myc-
TSC1 and HA-TSC2 caused by either cyclin D1 alone or cyclin D1-CDK6 (Fig. 4.5b). A 
three-fold increase in transfected cyclin D1 expression plasmid causes a correspondingly 
larger decrease in both myc-TSC1 and TSC2 levels (Fig. 4.5c), indicating that the effect of 
cyclin D1 on TSC1 and TSC2 protein levels is equivalent. We failed to inhibit cyclin D1-
mediated TSC1-TSC2 down-regulation with MG132, chloroquine, and leupeptin (data not 
shown), ruling out the potential involvement of the proteasome, lysosome, or calpain. 
Detection of either TSC1 or TSC2 is increased when co-expressed with the second TSC 
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complex member (Fig. 4.2b), suggesting that proper folding or protein stability requires 
TSC1-TSC2 complex formation. TSC1 and, to a lesser extent, TSC2, fractionate in an NP-
40-insoluble fraction when expressed alone, and are found predominantly in an NP-40-
soluble fraction when co-expressed (Fig. 4.5c; (Nellist et al., 2001). Cyclin D1 expression 
causes a dose-dependent shift of both TSC1 and TSC2 from the NP-40 soluble fraction to the 
insoluble fraction (Fig. 4.5c).  In addition, binding of ectopically expressed TSC2 and cyclin 
D1 is disrupted by co-expression of TSC1 (Fig. 4.2c, lanes 14, 16, 18), indicating that stable 
TSC1-TSC2 complex formation is incompatible with cyclin D1 association. Together, these 
data suggest that cyclin D1 overexpression is able to negatively regulate co-expressed TSC1 
and TSC2 via a CDK-independent mechanism, possibly through complex disruption. 
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Discussion 
 The “pRb pathway” controls the transition from the G1 to the S phase of the cell 
cycle and is often denoted as a linear sequence of interactions: INK4 proteins—|cyclin D-
dependent kinases—|pRb family proteins (Sherr and McCormick, 2002). The importance of 
this pathway is underscored by the likelihood that it is deregulated in most, if not all, human 
tumors. Interestingly, the aberrant activation of CDK4/6, by either loss of INK4 inhibitor 
genes or amplification and overexpression of cyclin D, CDK4, or CDK6 genes, is observed 
disproportionately more often than is inactivation of pRb proteins in diverse cancers. This 
observation suggests that inappropriate cyclin D-CDK4/6 activity confers more growth 
advantages to cells than mere loss of pRb function, and implies that inactivation of cyclin D-
CDK4/6 targets in addition to pRb may contribute to its oncogenic potency (Deshpande et al., 
2005).  We have shown that cyclin D, either alone or in conjunction with CDK6 can 
physically interact with the tumor suppressor protein, TSC2, and down-regulate the growth 
suppressive function of the TSC1-TSC2 heterodimer. 
 
 TSC1 and TSC2 were originally identified as two separate loci linked to the 
congenital disorder, tuberous sclerosis complex (TSC, (Consortium, 1993; van Slegtenhorst 
et al., 1997)). The in vivo function of TSC1-TSC2 had been difficult to pinpoint until studies 
in D. melanogaster identified the TSC genes (dTSC1 and dTSC2) as important regulators of 
cell growth (Gao and Pan, 2001; Potter et al., 2001; Tapon et al., 2001). Numerous studies, 
both in Drosophila and mammalian systems, have linked TSC1-TSC2 with several other 
gene products involved in the insulinÆPI3KÆAKTÆTOR cell growth signaling network 
(Gao and Pan, 2001; Gao et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 
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2001; Potter et al., 2002; Rosner et al., 2003; Tee et al., 2002). The TSC1-TSC2 complex is a 
key negative regulator of the TOR kinase activity, integrating diverse inputs from growth 
factors, oxygen and nutrient availability, and energy status. The TOR inhibitory activity of 
TSC1-TSC2 stems from the GAP (GTPase-activating protein) domain of TSC2, which 
inactivates the GTPase Rheb and prevents it from stimulating the kinase activity of mTOR 
(Garami et al., 2003; Inoki et al., 2003; Li et al., 2004; Saucedo et al., 2003; Stocker et al., 
2003; Tee et al., 2003; Zhang et al., 2003a). 
 
The coupling of cell division with cell growth in multicellular organisms, as opposed 
to unicellular organisms, intuitively requires more complex regulatory mechanisms (Conlon 
and Raff, 1999).  Whereas unicellular organisms must constantly adapt to changing nutrient 
and energy availability, cells of a muticellular organism are maintained within an 
environment of relatively constant and abundant nutrient and energy supply, and rely on 
extracellular cues, in the form of mitogenic or growth factor signaling, to drive cell division 
or cell growth, respectively.   Cyclins are regarded as potential “cell growth sensors” or 
“translational sizers” that may transmit growth stimuli to proliferative pathways since they 
are rate-limiting for cell cycle progression and their expression, or accumulation, is sensitive 
to the rate of protein synthesis (Fingar and Blenis, 2004; Jorgensen and Tyers, 2004).  Cyclin 
D might be considered a bilateral relay for proliferation signals since its activation of CDK is 
derived from mitogens and/or growth factors and because it can simultaneously promote cell 
cycle progression as well as cell growth (Fig. 4.6). 
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We have demonstrated that the TSC1-TSC2 heterodimer may be a molecular target of 
cyclin D-CDK’s growth control activity. An analogous association has also been observed in 
Drosophila where dTSC1 and dTSC2 have been found to interact genetically with cycD and 
CDK4  (Tapon et al., 2001). While dTSC1-dTSC2 over-expressed in the eye resulted in a 
pronounced reduction in overall eye size, co-overexpression of cyclin D-CDK4 rescued this 
defect. Interestingly, cyclin E co-overexpression was also capable of rescuing the small eye 
phenotype, and reduction in cyclin E or cyclin A levels resulted in even smaller eyes. These 
studies provide a premise to our findings that in mammalian cells cyclin D-CDK could act 
upstream of and inhibitory to TSC1-TSC2. Additionally, the studies in Drosophila also 
suggest the potential involvement of other cyclins in negatively regulating TSC1-TSC2. 
Consistent with this, we have detected interactions between TSC2 and cyclins A, B, and E 
(data not shown), and interactions between TSC2 and cyclin A, cyclin B, and CDK1 have 
been reported previously (Astrinidis et al., 2003; Catania et al., 2001). 
 
 The co-expression of TSC1-TSC2 with multiple cyclin-CDK wild-type pairs, but not 
kinase dead ones, results in the phosphorylation of both TSC1 and TSC2 (Fig. 4.4). Though 
in additional experiments we have failed to unambiguously demonstrate direct 
phosphorylation of TSC1 or TSC2 by cyclin D1-CDK4/6 (data not shown), we cannot 
exclude this possibility.  Astrinidis et al. described the direct phosphorylation of TSC1 by 
cyclin B-CDK1 in nocodazole treated cells (Astrinidis et al., 2003). The shared ability of 
multiple cyclin-CDK pairs to bind to, and possibly phosphorylate, TSC1-TSC2 suggests that 
throughout all stages of the cell cycle the TSC complex is under the negative regulation of 
cyclin-CDK complexes, ensuring continuous protein synthesis and growth to meet the needs 
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of a dividing cell. In fact, early studies have shown that growth of metazoan cells is not 
confined to a single phase of the cell cycle but rather is continuous throughout (Mitchison, 
2003).  Consistent with this, cells require a sufficient nutrient supply to pass the restriction 
point in G1.  However, once past the restriction point cells continue to divide even after 
nutrients have been withdrawn (Zetterberg et al., 1995).  
 
 The down-regulation, or decrease in detection, of TSC1 and TSC2 does not require 
their phosphorylation promoted by the co-expression of cyclin Ds-CDK4/6, nor does it 
require binding of CDK4/6 by cyclin D1 (Figs. 4.4 and 4.5). Cyclin D, therefore, appears to 
affect TSC1 and TSC2 through both kinase-dependent and kinase-independent mechanisms. 
The cyclin D-dependent down-regulation of TSC1-TSC2 coincides with their shift from a 
soluble to an insoluble fraction of cell lysate, consistent with a reduced ability of the TSC1 
and TSC2 monomers to form a dimeric complex (Nellist et al., 2001). Since the effect of 
cyclin D overexpression on TSC1 and TSC2 steady state levels was most pronounced on 
ectopically expressed proteins (data not shown), these data suggest that cyclin D might 
interfere with the folding of nascent TSC1 or TSC2, thereby preventing stable complex 
formation. The effect, if any, of cyclin D-CDK driven phosphorylation of TSC1 and TSC2 
might be masked by the CDK independent ability of cyclin D to down-regulate the TSC1-
TSC2 complex. 
 
 In summary, we have described the inhibition of the tumor suppressor complex 
TSC1-TSC2, a key negative regulator of mTOR activity, by cyclin D1, itself a well known 
proto-oncogene frequently amplified in various types of human cancers. mTOR stimulates 
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cell growth through ribosome biogenesis and activity, and the importance of its regulation in 
suppressing unrestrained cell growth and proliferation is manifest in many cancers (Ruggero 
and Pandolfi, 2003). Further study of the cellular setting(s) and mechanism(s) whereby cyclin 
D1, with or without its CDK partners, is able to antagonize TSC1-TSC2 activity will be 
crucial to our understanding of the interplay between cell cycle and cell growth regulation, 
and may validate the targeting of mTOR in tumors where cyclin D1 is over-expressed. 
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Materials and Methods 
Construction of yeast three-hybrid system.  To conduct a yeast three-hybrid screen, two 
vectors, pGBT6 and pGBT7, were constructed.  Both plasmids were derived from pGBT8, a 
modified form of pGBT9 that has been widely used for two-hybrid screening.  pGBT8 was 
cut with the restriction enzymes XhoI and PstI and the vector backbone was gel purified.  
This fragment was then ligated to two annealed oligonucleotides, pGBT-3 and pGBT-4 
(pGBT-3 sequence is: 5’ TCG AGG CCT GAT CAT GGC CAC TAG TGG TAC CGC 
GGA TCG ATG CA 3’; PGBT-4 sequence is: 5’ TCG ATC CGC GGT ACC ACT AGT 
GGC CAT GAT CAG GCC 3’).  A 915 bp AatII restriction fragment was generated from 
pGBT8 by PCR that contains an ADH promoter followed by a sequence encoding a nuclear 
localization signal (NLS, the first 73 amino acids of the GAL4-BD), a unique MCS and the 
ADH termination sequence.  These primers were GBT-5 and GBT-6 (GBT-5 sequence is 5’ 
TAG ACG TCG CTT GCA TGC AAC TTC 3’; GBT-6 is 5’ ATG ACG TCC GGC ATG 
CCG GTA GAG GTG 3’).    This cassette was inserted into the AatII site of pGBT8, 
resulting in pGBT7.  A similar experimental methodology was used to generate pGBT6 that 
does not retain the NLS.  Both pGBT7 and pGBT6 were confirmed by restriction mapping 
and partial sequencing. 
 
Yeast three-hybrid assays.   The HF7c strain of S. cerevisiae was co-transformed with bait 
and prey plasmids and grown on selective media.  Additional growth assays were performed 
as above in the presence of either 10mM or 30mM 3-amino-triazole. beta-galactosidase 
assays were performed according to the manufacturer’s instructions (Clontech).   
 91
Cell Culture, transfections, plasmids, and reagents.   Saos-2, U2OS, or HEK293T cells were 
grown at 37º C with 5%CO2 in Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented 
with 10% fetal bovine serum (Sigma), penicillin, and streptomycin (Invitrogen).  Cells were 
transiently transfected using the calcium phosphate precipitation method, or Lipofectamine 
(Invitrogen) or FuGene (Roche) according to the manufacturers’ instructions.  After 
transfection cells were typically cultured for 24-48 hours prior to treatment or harvest for 
flow cytometry, immunoprecipitation (IP), or Western analysis.  To serum-starve cells, 
transiently transfected cells were cultured in DMEM without serum overnight (18 hours), 
followed by re-stimulation with 10% serum over a 4 hour timecourse. The cDNA encoding 
rat TSC2 was kindly provided by Dr. Ray Yeung, and was subcloned into pcDNA3 in-frame 
with an HA-epitope tag.  Flag-tagged human TSC2 was kindly provided by Dr. Lewis 
Cantley.  Full-length cDNA encoding human TSC1 was PCR amplified from a HeLa cDNA 
library and subcloned in-frame with a Myc-epitope tag.  Constructs encoding HA-p70S6K 
and HA-4E-BP1 were kindly provided by Dr. Kun-Liang Guan and Dr. John Blenis, 
respectively.  Those encoding cyclins D1, D2, D3, E1,and A2, CDKs 1, 2, 2K33M, 4, 6, 6K43M, 
and GFP-spectrin are from lab stocks.  Site-directed mutagenesis of cyclin D1 was performed 
by standard PCR techniques using the QuikChange kit (Stratagene).  All constructs were 
verified by partial DNA sequencing. 
 
Flow cytometry.   Cells were transiently transfected with cDNAs of interest along with GFP-
spectrin, cultured for 48 hours, collected by trypsinizing, washed and resuspended in cold 
PBS, and fixed by adding EtOH to a final concentration of 75%.  Fixed cells were 
resuspended in PBS/ 0.1 % Triton/ 0.1 mg/mL RNase, and DNA was labeled with propidium 
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iodide (1 mg/mL) overnight at 4º C.  Prepared cells were analyzed using a flow cytometer 
(FACScan, Becton-Dickinson), gating specifically on GFP-positive, transfected cells, using 
Summit software (version 3.0, BD Biosciences) for data processing. 
 
Immunochemistry procedures and antibodies.   Cells analyzed by Western blot or IP were 
lysed in NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 0.15 M NaCl, 0.5% Nonidet P-40, 1 mM 
PMSF, 1 mM dithiothreitol, 50 m M sodium fluoride, 1 m M sodium vanadate, and protease 
inhibitors: 2 µg/ml aprotinin, 2 µg/ml leupeptin, 10 µg/ml trypsin inhibitor, and 150 µg/ml 
benzamidine) and cleared by centrifugation.  NP-40 insoluble fractions were solubilized 
using an SDS lysis buffer (50 m M Tris-HCl pH 7.5, 0.5 m M EDTA, 1% SDS, 1 mM PMSF, 
1 mM dithiothreitol, 50 m M sodium fluoride, 1 m M sodium vanadate, and protease 
inhibitors).  Extracts treated with CIP (Calf Intestinal alkaline Phosphatase, 25 units; NEB) 
were prepared by lysing cells in NP-40 lysis buffer lacking sodium vanadate and sodium 
fluoride.  Clarified total cell lysates were quantified using BioRad protein assay kits.  
Immunoprecipitations were incubated overnight at 4º C, using 0.5-1 mg of total protein lysate, 
1-2 ug affinity purified antibody, and Protein A or G agarose beads (Invitrogen). Western 
blotting was performed with 50-100 µg of protein extract separated by SDS-PAGE and 
transferred to nitrocellulose membrane (Osmonics, Inc.). Polyclonal antibody to TSC2 was 
raised in rabbits (Pocono Rabbit Farms, PA) using a C-terminal TSC2 peptide (corresponding 
to residues 1788-1807) coupled to KLH as an immunogen, and later affinity purified (Pierce 
Biotechnology).  Rabbit polyclonal antibodies to cyclin D1/2, cyclin D3, CDK6, and p16 
were similarly generated by our lab. Affinity-purified antibodies to Myc (clone 9E10, 
NeoMarkers), HA (clone 12CA5, NeoMarkers), Flag (M2, Sigma), cyclins D1, D2, D3 
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(G124-259, PharMingen), tubulin (NeoMarkers) and phosphorylated Thr389 of S6K (#9205, 
Cell Signaling Technologies) were purchased commercially.  
 
In vivo phosphorylation and kinase assays.  Transiently transfected cells were grown for 48 
hours, and then depleted of phosphate by culturing in phosphate-free DMEM (Gibco) for 2 
hours. 100 μCi 32P-orthophosphate was added to media and cells were incubated for 30 
minutes.  Cells were rinsed twice with phosphate buffered saline and lysed using NP-40 lysis 
buffer.  Anti-HA immunoprecipitates were purified and separated by SDS-PAGE.  The gel 
was stained with coomassie blue to determine equal loading of protein, then dried and 
analyzed by autoradiography. For kinase assays 293T cells in 6-well plate were transfected as 
indicated and serum starved for 2 to 8 hours. One half of anti-HA- immunoprecipitate was 
used for Western blot analysis and the other half was washed twice in kinase assay buffer (20 
mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM DTT) and incubated with 0.5 μg GST-S6 and 50 
μM ATP, and 2 μCi [32]P-γ-dATP and incubated for 15 minutes at 30˚C. Reactions were 
separated by SDS-PAGE, dried and visualized by autoradiography.  
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Figure Legends 
Figure 4.1. D-type cyclins interact with the C-terminus of TSC2. (A) Yeast three-hybrid 
assay was performed by cotransforming yeast with TRP+ plasmids encoding “bait,” listed 
first and fused to GAL4DB along with LEU+ plasmids encoding “prey,” listed second and 
fused to GAL4AD. Transformed yeast were plated on selective media to confirm expression 
(middle panel) and positive interaction (HIS+, right panel).  Where two “bait” proteins are 
indicated, both were expressed from a single TRP+ plasmid. (B) Directed yeast two- or three-
hybrid assay was performed as in (A). 
 
Figure 4.2. TSC2 co-immunoprecipitates with cyclin D. (A) 293T cells were transfected with 
plasmids encoding Flag-TSC2 and/or the indicated cyclin D. Whole cell lysate (lanes 1-3) or 
anti-Flag immunoprecipitates (lanes 4-7) were separated by SDS-PAGE and blotted with 
antibody against TSC2 (upper panel) or cyclins D1-3 (lower panel). (B) Myc-cyclin D1 was 
divided into three domains (amino acids 1-42, pRb binding; 42-153, cyclin box; 153-295, C-
terminus), expressed in 293T, and immunoprecipitated with anti-Myc antibody to test for 
association with co-transfected HA-TSC2. Equal expression of HA-TSC2 was confirmed in 
whole cell lysates (data not shown).  (C) 293T cells were transfected with equal amounts of 
HA-TSC2 cDNA with or without Myc-TSC1 and/or cyclin D1 cDNAs. Following treatment, 
whole cell lysate (lanes 1-12) or anti-cyclin D1 immunoprecipitates (lanes 13-18) were run 
on SDS-PAGE and analyzed by Western blot as indicated.  
 
Figure 4.3. Cyclin D-CDK4/6 abrogates the growth inhibitory effects of TSC1-TSC2. (A) 
U2OS were transfected with GFP-spectrin alone (control), or with GFP-spectrin, TSC1 and 
TSC2, with or without cyclin D1, and analyzed 48 hours later by flow cytometry to assess 
cell cycle and cell size (FSC) profiles.  Shown here is the cell size distribution of G1 phase 
cells.  Results are representative of three independent experiments.  (B)  HA-4E-BP1 was 
transiently expressed in 293T alone, or with cyclin D1 and CDK4.  After 24 hours, cells were 
either left untreated, or were starved of serum for 1 hour prior to harvest. Whole cell lysates 
were run on SDS-PAGE and blotted with anti-HA antibody.  (C)  293T cells were transfected 
with empty vector or HA-S6K, with or without cyclin D1 and CDK4, and cultured for 24 
hours under normal growth conditions.  Before harvest, cells were either left untreated (0 
hour), or were serum-starved for 2, 4, or 8 hours.  HA-S6K was immunoprecipitated from 
each total cell lysate; one quarter was separated by SDS-PAGE and probed with anti-HA 
antibody (lower panel), and the remainder of each IP was used in a kinase assay with purified 
GST-S6 and 32P-ATP, separated by SDS-PAGE, and analyzed by autoradiography (upper 
panel).  The band intensities of 32P -GST-S6 were quantified by densitometric analysis, and 
represented as relative units (lowest panel).  (D)  U20S were transfected with the indicated 
plasmids, harvested 48 hours later, and analyzed by SDS-PAGE and Western, blotting with 
anti-HA, anti-Myc, and anti-phosph-T389-S6K antibodies. 
 
Figure 4.4.  CDKs promote the phosphorylation of TSC1 and TSC2.  (A)  Saos-2 cells were 
transiently transfected with plasmids encoding HA-TSC2-C, cyclin D1, and/ or CDK4 and 
metabolically labeled with [32]P-orthophosphate.  HA-TSC2-C was immunoprecipitated, 
separated by SDS-PAGE, and analyzed by autoradiography.  Equal loading of protein per 
lane was confirmed by Coomassie blue staining (data not shown).  (B) U2OS were 
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transfected with plasmids encoding myc-TSC1 and TSC2, alone or in conjunction with 
various cyclin-CDK combinations, and whole cell lysates were separated by SDS-PAGE and 
analyzed by Western blot.  (C)  U2OS were transfected with the indicated plasmids and 
analyzed as in (B), except that each whole cell lysate was either treated with 25 units CIP, or 
left untreated. 
 
Figure 4.5.  Down-regulation of TSC1-TSC2 by cyclin D.  (A) Myc-TSC1 and HA-TSC2 
were ectopically expressed in U2OS alone, or in conjunction with WT or mutant (K112E) 
cyclin D1.  Total cell lysates were analyzed by SDS-PAGE and Western blot, as indicated.  
(B) U2OS were transiently transfected with plasmids encoding HA-TSC2 and Myc-TSC1, 
along with cyclin D1 and/or CDK6, and p16 or HA-p21, as indicated, and analyzed by SDS-
PAGE and Western blot, probing with anti-HA, -Myc, -CDK6, -cyclin D1, -p16, and –
tubulin antibodies.  (C) U2OS were transiently transfected with 100 ng each of pcDNA3-
Myc-TSC1 and pcDNA3-HA-TSC2 alone, or with 100 ng or 300 ng (3x) pcDNA3-cyclin D1.  
Transfected cells were collected and lysed in NP-40 lysis buffer (soluble fraction), and the 
remaining pellet (insoluble fraction) was solubilized in an SDS lysis buffer.  The resulting 
samples were run on SDS-PAGE and analyzed by Western blot. 
 
Figure 4.6. Model of cyclin D-CDK4/6 activity in cell division and growth.  Early in G1, 
mitogenic and growth factor signaling induce the synthesis of D-type cyclins, leading to 
activation of cyclin D-CDK4/6.  The INK4 family of CDK inhibitor proteins is induced by 
as-yet-undefined pathways and specifically inhibits CDK4/6.   When activated, cyclin Ds-
CDK4/6 and cyclin Es-CDK2 (not shown here) cooperatively phosphorylate pRb family 
proteins, derepressing E2F to allow transcription of E2F target genes, thereby permitting G1 
to S transition.  In concert, cyclin D-CDK4/6 may also inactivate the TSC1-TSC2 
heterodimer, thereby activating the TOR growth signaling pathway.  Thus cyclin D-CDK4/6 
may be seen as a bilateral relay for proliferation signals, integrating mitogenic and growth 
factor signaling to stimulate DNA synthesis as well as protein synthesis, thereby driving both 
the cell cycle and cell growth.  Proto-oncogenic proteins are shaded in gray and tumor 
suppressor proteins in black.   
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Figure 4.1.  D-type cyclins interact with the C-terminus of TSC2 
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Figure 4.2. Co-immunoprecipitation of TSC2 and cyclin D
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Figure 4.4.  CDKs promote the phosphorylation of TSC1 and TSC2 
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Figure 4.5.  Down-regulation of TSC1-TSC2 by cyclin D 
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Figure 4.6. Model of cyclin D-CDK4/6 activity in cell division and growth. 
Zacharek et al. Fig. 6 
  
 
 
 
 
CHAPTER V 
 
Evaluating the potential control of TSC1-TSC2 by the cell cycle 
machinery in vivo 
 
 
TSC1 and TSC2 are important regulators of cell growth, integrating signaling 
resulting from nutrient and oxygen availability, cellular stress, energy status, and growth 
factor signaling.  Our studies in chapter IV suggest another possible input into the TSC1-
TSC2 growth regulatory node that stems from the cell cycle machinery. Evidence from 
Drosophila had also previously suggested that cyclin D and CDK4 could interact genetically 
with TSC1-TSC2, and that cyclin D-CDK4 have critical functions in cellular growth control, 
in addition to roles in cell cycle regulation (Datar et al., 2000; Kozar et al., 2004; Meyer et al., 
2000; Tapon et al., 2001).  We have shown that over-expression of D-type cyclins and 
CDK4/6 can regulate the ability of ectopically expressed TSC1-TSC2 to control cellular 
growth of tissue culture cells (chapter IV).  Whether this regulatory interaction occurs in vivo, 
however, is still unclear. 
 
CDK-independent down-regulation of TSC1-TSC2 by D-type cyclins 
The ability of over-expressed D-type cyclins to down-regulate ectopically expressed 
TSC1 and TSC2 appears specific, since the effect is dose-dependent, and the stability of 
several other co-expressed proteins, including HA-ARF and HA-S6K, was unaltered by 
cyclin D1 over-expression (Fig. 5.1).  Conversely, expression of a number of different 
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proteins other than cyclins, such as GFP, CDK inhibitors, or p70S6K, to name a few, had no 
effect on protein levels of co-expressed TSC1-TSC2 (data not shown). 
 
In order to test whether TSC1-TSC2 protein levels are regulated by cyclin D1 in vivo, 
we evaluated endogenous levels of TSC1 and TSC2 in cell types which endogenous cyclin 
D1 levels were altered (Figs. 5.2, 5.3, 5.4, 5.5).  Early passage cyclin D1 null MEFs (mouse 
embryo fibroblasts) were lysed, and TSC2 protein levels were assessed (Fig. 5.2).  Full-
length TSC2 levels in cyclin D1 null MEFs were found to be similar to those observed in 
wild type MEFs.  Lower molecular weight bands of TSC2 of ~85 kDa and ~100 kDa were 
also detected by C-terminal- or N-terminal-specific anti-TSC2 antibodies, respectively, in 
WT MEFs but not in cyclin D1 null MEFs.  Since the combined sizes of these bands 
approximately add up to the molecular weight of full-length TSC2, they could potentially 
represent cleavage products produced in WT cells, but not in cyclin D1 null MEFs.  However, 
when cyclin D1 expression was restored in the cyclin D1 null MEFs by retroviral expression, 
the lower molecular weight bands were not observed (data not shown); therefore, the identity 
and function of the 85 kDa and 100 kDa bands are unclear, and the disruption of cyclin D1 in 
MEFs does not appear to alter TSC2 protein levels. 
 
In the opposite case, in which various cancer cell lines expressing elevated cyclin D1 
levels (MCF7, breast; A431, cervix; FaDu, pharynx; and U2OS, bone) were compared to 
other cell lines expressing cyclin D1 within a normal range (293T, kidney; HeLa, cervix; 
C33A, cervix, SAOS2, bone), TSC1 and TSC2 levels did not appear to correspond with 
cyclin D1 levels (Fig. 5.3).  Phospho-T389-p70S6K levels, which are dependent on active 
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mTOR (and therefore expected to be elevated under conditions in which TSC1-TSC2 activity 
is reduced), were also assessed in this panel of cell lines, but also failed to show any 
correlation with cyclin D1 levels.  The stability of TSC1 and TSC2 is dependent on their 
heterodimerization, and disruption of their association is destabilizing (Inoki et al., 2003; 
Inoki et al., 2002); (chapter IV).  Therefore, we assessed the binding between TSC1 and 
TSC2 in several of these cell lines, but did not observe any alterations in their association in 
the presence of amplified cyclin D1 (Fig. 5.4).  However, it is difficult to interpret 
comparisons between protein levels and interactions derived from different cell types.  
Comparisons between two cell lines of common origin, such as the osteosarcoma cell lines 
U2OS and SAOS2, may be more valid; TSC1 (and to a much lesser degree, TSC2) levels do 
in fact appear to be reduced in U2OS cells, in which cyclin D1 levels are elevated, relative to 
SAOS2 cells, which express normal levels of cyclin D1.  Perhaps a more comprehensive 
analysis of TSC1-TSC2 levels and activity in tissue type-matched cells with or without 
cyclin amplification would more clearly establish whether cyclins participate in regulating 
TSC function in vivo. 
 
When the same panel of cell lines described above was subjected to cyclin D1 RNAi, 
endogenous TSC1 and TSC2 levels were not stabilized (Fig. 5.5).  Collectively (Figs. 5.2, 5.3, 
5.4, 5.5), these data suggest that cyclin D1 is insufficient to control endogenous TSC1 and 
TSC2 protein levels.  These findings corroborated with additional observations of the cell 
cycle protein expression profiles of TSC1 and TSC2.  It could be expected that if D-type 
cyclins alone were able to regulate the stability of TSC1 and TSC2, TSC levels would be 
decreased during the stage in which cyclin D1 levels are up-regulated (G1 phase).  However, 
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TSC1 and TSC2 levels did not fluctuate significantly during the course of the cell cycle in 
the primary cell line NHF2 (Fig. 5.6). 
 
Potential involvement of other cyclins in the regulation of TSC1-TSC2 
Recent reports have suggested that TSC1 and TSC2 may interact with cyclins other 
than cyclin D (Astrinidis et al., 2003; Catania et al., 2001).  Therefore, I tested whether TSC2 
could associate with other cyclins.  TSC2 and cyclins A1, B1, D1, E1, and N1, with or 
without CDK1, CDK2, CDK6, or CDK10, were ectopically expressed in 293T cells.  IP-
Western analysis revealed that each cyclin co-immunoprecipitated with TSC2 (Fig. 5.7).  
Other cyclins were also found to down-regulate TSC1-TSC2 levels (data not shown).  
Therefore, the lack of variance in TSC1 and TSC2 protein levels during the cell cycle (Fig. 
5.6) could be explained by a potential continuum of cyclins that associate with and modulate 
the activities of TSC1 and TSC2 during the course of the cell cycle (see chapter IV). 
 
Potential phosphorylation of TSC1 and TSC2 by multiple cyclin-CDKs 
  Significant shifts in mobility have also been observed when several different CDKs 
were co-expressed with their cyclin partners and TSC1-TSC2; cyclin E1-CDK2, for example, 
clearly promoted the phosphorylation of TSC2 (lane 9, Fig. 5.7).  Phosphorylation of both 
TSC1 and TSC2 has in fact been observed to be induced upon co-expression with CDK1, 
CDK2, CDK4, and CDK6 (chapter IV; data not shown).  These experiments have typically 
been performed using asynchronous populations of cells, which appears to affect the 
occurrence of CDK-induced phosphorylation of TSC1 and TSC2 (Fig. 5.7; data not shown).  
Most frequently, however, TSC1 seems to be more highly phosphorylated than TSC2 when 
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co-expressed with cyclins-CDKs, as in Figure 5.8 (lane 5), in which TSC1 is prominently 
phosphorylated when co-expressed with cyclin D and CDK6, but not with the catalytically 
inactive mutant CDK6K43M, or in the presence of p16 (lanes 6,7). 
 
Although kinase assays designed to test the direct phosphorylation of TSC2 by 
CDK4/6 have been inconclusive (data not shown), we have not yet analyzed the direct 
phosphorylation of TSC2 or TSC1 by the other CDKs.  TSC1 in fact is a heavily 
phosphorylated protein (data not shown); (Sarbassov dos et al., 2005), which contains 3 
putative CDK consensus sites, while TSC2 contains only one (Ballif et al., 2005); (Scansite).  
While TSC2 has been shown to be phosphorylated by numerous kinases, including AKT, 
AMPK, ERK, p90RSK, and MK2, the study of the kinases involved in phosphorylating TSC1 
has been lagging and are largely unknown.  Therefore, a more comprehensive analysis and 
mapping of direct phosphorylation of TSC2 and especially TSC1 by the CDKs is warranted.  
Given the redundancy of function of the CDKs (Pagano and Jackson, 2004), it will be 
challenging to decipher which CDKs act to phosphorylate TSC1 or TSC2 under normal 
physiological conditions, and in which contexts, but such insight will undoubtedly aid in our 
understanding of crosstalk between the cell cycle and cell growth machineries. 
 
Analyzing the consequence of the cyclin/CDK—TSC1/TSC2 interaction in vivo 
Aside from assessing the phosphorylation status of TSC1-TSC2 as a readout of 
regulation by cyclins-CDKs, the recent finding that TSC2 acts as a GAP (GTPase activating 
protein) specifically toward the small GTPase Rheb (Kwiatkowski and Manning, 2005) has 
provided a direct functional assay by which to assess TSC1-TSC2 function.  Preliminary 
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studies designed to test the impact of cyclin D-CDK4 on endogenous Rheb activity (Fig. 5.9) 
support our conjecture that cyclin D-CDK4 can influence the function of TSC1-TSC2 in 
regulating cell growth effectors.  Rheb has been detected in vivo to have a highly active basal 
state that is predominantly GTP-bound (Li et al., 2004).  HA-Rheb ectopically expressed in 
293T cells, purified, and analyzed by thin layer chromatography was primarily GTP-bound, 
as expected (Fig. 5.9, lane 1).  Upon serum starvation, TSC1-TSC2 is activated, thereby 
increasing levels of GDP-bound Rheb (Fig. 5.9, lane 2).  Under serum-starved conditions, the 
co-expression of cyclin D-CDK4 (but not the kinase dead complex of cyclin D-CDK4R31C, 
lane 4), with HA-Rheb shifted its activity back to a more highly GTP-bound state (Fig. 5.9, 
lane 3).  By assaying Rheb function, it is now possible to directly analyze the function of 
TSC1-TSC2.  Extending these studies to assess endogenous Rheb activity in vivo, in different 
contexts in which cyclin D or CDK4/6 (or other cyclins-CDKs) are aberrantly over-expressed 
or activated, or in which CDK inhibitors are inactivated, will broaden our understanding of 
the impact of dysregulated cell cycle machinery on cell growth control during tumorigenesis. 
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Figure 5.1 Down-regulation of TSC1/TSC2 by cyclin D is dose-dependent and appears specific.  
U2OS cells were transfected with plasmids myc-TSC1/ HA-TSC2, HA-S6K, or HA-ARF, plus 
increasing amounts of cyclin D, to assess the specificity of regulation of TSC1/TSC2 by cyclin D1.  
Western blotting revealed a graded reduction in TSC1/TSC2 levels by increasing levels of cyclin D1 
expression, while levels of HA-S6K and HA-ARF were unaffected by cyclin D1 overexpression.
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Figure 5.2. TSC2 protein levels are not elevated in cyclin D1 null MEFs.  Lysates from cyclin D1 
null (-/-) and wild type MEFs (mouse embryo fibroblasts) were analyzed by Western, probing for 
TSC2 using anti-TSC2 antibodies specific for the C-terminus or N-terminus of TSC2.  Levels of full 
length TSC2 were unaltered in cyclin D1 null cells.  Lower molecular weight bands of ~85 kDa and 
100 kDa were detected by the anti-TSC2 (C-term) and anti TSC2 (N-term) antibodies, as indicated, in 
wild type but not in cyclin D1 null MEFs.    
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Figure 5.3.  Cell lines over-expressing Cyclin D do not show decreased endogenous 
protein levels of TSC1/ TSC2.  Cell lines expressing wild type levels (293T, HeLa, 
C33A, SAOS2) and amplified levels (MCF7, A431, FaDu, and U2OS) of cyclin D1 
were analyzed by Western blot, probing for the indicated proteins; P-T389 S6K is a 
readout of mTOR function.  Several cell lysates were loaded in duplicate. 
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Figure 5.4.  Elevated levels of Cyclin D1 do not affect the interaction between 
TSC1 and TSC2. Binding between TSC1 and TSC2 in cell lines with wild type 
(C33A, HeLa) versus amplifed (MCF7, FaDu) levels of cyclin D1 was assayed by 
immunoprecipitation using anti-TSC1 antibody, resolved by SDS-PAGE, and analyzed 
by Western blot.
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Figure 5.5.  RNAi of Cyclin D1 in various cell lines does not increase steady state levels of 
TSC1/ TSC2.   Cyclin D1 was silenced using synthetic siRNAs, and TSC1/TSC2 levels were 
assessed by Western blot.
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Figure 5.6.  TSC1 and TSC2 protein levels do not significantly fluctuate over the course of the 
cell cycle in NHF2 cells.  Following serum starvation of NHF2 cells to allow synchronization in 
G0, the cells were restimulation with serum, and collected over a timecourse of 30 hours.  pRb and 
cyclins A and D1 were immunostained to confirm effective synchronization. 
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Figure 5.7.  TSC2 not only co-immunoprecipitates with cyclin D, but also with cyclin A, 
cyclin B, cyclin E, and cyclin N.  293T cells were transfected with plasmids encoding HA-
TSC2, along with HA-cyclin A1, Myc-cyclin B1, cyclin D1, Myc cyclin E1, or HA-cyclin
N, with or without its CDK binding partner (HA-CDK1, Myc-CDK2, CDK6, or CDK10).  
These ectopically expressed cyclins were immunoprecipitated using anti-myc (M), anti-HA 
(H), or anti-cyclin D1 antibodies, and analyzed by Western blot.  
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Figure 5.8.  TSC1 is highly phosphorylated in response to cyclin D-CDK6 co-
expression.  U2OS cells were transfected with the indicated cDNAs (mut CDK6 is a 
catalytically inactive mutant), treated with the proteasome inhibitor MG132 for 4 hours, 
lysed, and evaluated by Western.
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Figure 5.9.  Cyclin D-CDK4 positively regulates Rheb GTPase activity.  293T cells were 
transfected with plasmids encoding HA-Rheb alone, or with cyclin D1 and CDK4 (wild type or 
catalytically inactive mutant, CDK4R31C).   48 hours post-transfection, the culture media was replaced 
with phosphate-free media, with or without serum, for 1 hour; metabolically labeled with 32P-
orthophosphate for 4 hours, and lysed.  HA-Rheb immunoprecipitates were purified, bound GDP/ 
GTP was eluted, and resolved by thin layer chromatography.
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CHAPTER VI 
 
Conclusions 
 
Implications of the dysregulation of cell growth and ubiquitination in cancer 
The dysregulation of cell growth is an often over-looked but important contributing 
factor in tumorigenesis, given the frequent targeting of the PI3K-AKT-TOR pathway in 
cancer.  Though cell growth is separable from the cell cycle, these processes are closely tied.  
Our studies of the interaction between cyclin-CDKs and TSC1/TSC2 demonstrate a potential 
link between the cell cycle and cell growth signaling networks (chapters IV, V).  Therefore, 
disruption of the CDK inhibitor—cyclin—CDK cell cycle machinery in neoplastic 
progression can have implications that extend beyond pRb to include the cell growth 
signaling pathway, and points to the targeting of cell growth pathways, i.e. by the mTOR 
inhihitor rapamycin, in such cancer settings. 
 
Our studies of the CUL4DDB1 E3 ligase in Drosophila have also unexpectedly 
indicated its potential involvement in regulating cell growth (chapters II, III).  Though the 
relevant substrates targeted by the CUL4DDB1 E3 ligase are as yet unknown, they likely 
represent negative regulators of growth, and can be easily tested using our existing piccolo 
DDB1 fly model system.  CUL4 is a gene of pleiotropic function whose gene product 
unquestionably assembles a wide array of E3 ligase complexes, to target an even larger array 
of substrates for ubiquitination.  The analysis of CUL4 and DDB1 mutants in Drosophila 
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have reinforced this idea, and established the CUL4DDB1 ligase as an important regulator of 
proliferation and development.  The CUL4DDB1 ligase plays a role in replication licensing by 
regulating CDT1 levels during the cell cycle, and appears to be required for proper hemocyte 
differentiation and development (chapter II).  Our genetic analysis has also indicated that 
CUL4 carries additional functions that are independent of DDB1, which has also been 
suggested by studies in S. pombe (Horn et al., 2005; Jia et al., 2005; Li et al., 2005; Thon et 
al., 2005).  Thus CUL4 has been linked to other functions such as regulating heterochromatin 
formation, and given its likely interaction with SAP130 and CPSF160, may also be involved 
in regulating mRNA processing events. Finally, CUL4 plays an important role in response to 
genotoxic stress by regulating XPC, histone H2A, Chk1, and CDT1, and allowing repair of 
damaged DNA to proceed.  Therefore, the dysregulated amplification or over-expression of 
CUL4 in cancer would have broad implications, affecting the ability of the cell to repair 
damaged DNA, control cellular growth and proliferation, or properly differentiate.  The 
identification of additional substrates that are targeted by CUL4-dependent E3 ligases will 
contribute to our understanding of the oncogenic function of CUL4A in settings such as 
breast cancer.   
 
 
A better understanding of cyclin D-CDK4/6 and CUL4-dependent E3 ligases and 
their downstream effectors will add to the growing knowledge of the pathways altered in 
tumorigenesis.  It is becoming clearer that there is a recurring collection of cellular hubs that 
are disrupted in the process of driving aberrant proliferation.  The challenge then will be to 
understand how these hubs are connected within a larger signaling network, and to envision 
how together they create the tumor cell phenotype, so that we can develop therapeutic 
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strategies to eliminate it (O'Shea, 2005).  Efforts are also currently underway to 
quantitatively model normal versus neoplastic cell signaling networks, taking into account in 
vivo data from the past several decades and the from the advent of high throughput 
expression and interactome data.  These novel systems-level approaches seem to be 
propelling us into a new computational era, leading to better-defined signaling networks and 
improving our predictive capabilities on rational drug targeting in cancer. 
 
Looking ahead 
Such efforts will hopefully aid in our gaining a better appreciation of the unique 
vulnerabilities of cancer cells.  Cancer cells have in fact been characterized as being highly 
dependent, or ‘addicted’ to the oncogenes or alterations in tumor suppressor genes that acted 
to drive their growth.  Addiction to oncogenes and hypersensitivity to tumor suppressor 
genes indicates that tumor progression is not simply an additive process of the responsible 
genetic alterations, but rather a complex process dependent on interactions due to the cellular 
and microenvironmental context (Weinstein, 2002).  Such addictions reveal points of 
susceptibility in cancer treatment.  For example, cancers in which the p53 pathway has been 
inactivated are particularly sensitive to the reintroduction of wild type p53, or inhibition of 
Bcl2 (Bykov et al., 2003).  Similarly, cancer cells in which the apoptotic program had been 
inactivated due to the over-activation of the PI3K/AKT pathway (but not by other parallel or 
downstream pathways) respond favorably to the mTOR inhibitor rapamycin, by re-activating 
the apoptotic program (Wendel et al., 2004; Wendel and Lowe, 2004).  Such observations 
reinforce the rationale for recent initiatives to map out the aberrations common to the 
different tumor types, and the eventual goal of mapping of an individual cancer patient’s 
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neoplastic alterations, so as to allow tailoring of cancer therapy to individual neoplastic 
disease (Lowe et al., 2004). 
 
A large scale endeavor to map the Cancer Genome Atlas is currently underway, 
whose organizers aspire to scan the genomes of tumors and catalog the genetic alterations 
associated with cancer.  The p53 mutation databases have already helped enumerate key 
alterations in the oncogenic process, and serve as a paradigm for future analyses of other 
important tumor suppressor genes, caretaker genes, and oncogenes (Soussi, 2005; Soussi et 
al., 2006). 
 
Currently, we are now aware of some of the genes dysregulated in tumorigenesis, but 
we are still unaware of the identity of the cell population(s) susceptible to tumorigenesis for 
the majority of human cancers (Polyak and Hahn, 2006).  The cell population(s) affected in 
tumorigenesis generally have attributes typically associated with stem cells: they are 
multipotent cells that self-renew limitlessly, and they also have the capacity to differentiate. 
Many signaling pathways implicated in the maintenance of normal stem cells are in fact 
found to be mutated in human cancers.  However, the true nature of the cancer stem cell is 
still unclear; whether the cancer stem cell only phenotypically resemble a stem cell or 
whether the cancer stem cell represents an altered early progenitor cell, is currently being 
investigated.  
 
With a better understanding of the cellular origins and signaling events driving tumor 
progression in patients, along with the development of methods to streamline the detection an 
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individual’s unique polymorphisms (Gresham et al., 2006) so that the contribution of our 
genetic backgrounds can be taken into account in managing disease, we seem to be entering a 
new era of highly individualized, targeted treatments.  The National Cancer Institute recently 
revealed an initiative to reduce the death and suffering due to cancer within the next ten years; 
it seems that their goal could just be attainable. 
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